INSIDE:

Update: Catheter-related bloodstream infection rates in relation to clinical practice and needleless device type

Infection prevention and control learning preferences of nurses sampled at a teaching hospital

The Canadian Journal of Infection Control
Revue canadienne de prévention des infections

The official journal of the Community and Hospital Infection Control Association – Canada
Association pour la prévention des infections à l’hôpital et dans la communauté – Canada
C. DIFFICILE OUTBREAK MANAGEMENT

IN CASE OF EMERGENCY

REScue™ BREAKS THE CHAIN OF INFECTION

REScue™ is the only DIN registered ready-to-use surface Sporicide. Visit the C. difficile OUTBREAK section at www.virox.com for information on products, protocols, references, support documents and endorsements, or call 1-800-387-7578.

Virox™ Accelerated Hydrogen Peroxide

Engineering Revolutionary Disinfectants for the War Against Microbes.
The Future is Clear

Introducing the First and Only Clear Positive Displacement Connector

Angus MEDICAL
1 (866) 418-1689 angusmedical.com

Max Plus Clear

Connect with Confidence.
MaxPlus Clear provides complete visualization of the fluid path providing a clear reminder to prime & purge all air, disinfect better and flush completely. Clarity enhances practice, reducing the occurrence of bloodstream infections and occlusions. Thus, enhancing patient care.

930 Wanamaker Ave, Ontario, CA 91761-8151
Phone (909) 390-9080 Toll Free (800) 780-0012 Fax (909) 605-5894 www.maximusmedical.com

*MaxPlus® and MaxPlus Clear™ are trademarks of Medegen, Inc.*
Source control for prevention of hospital-acquired infections

Decolonize skin with Sage Antiseptic Body Cleanser 2% Chlorhexidine Gluconate (CHG) in a premoistened washcloth!

Bathing with Sage Antiseptic Body Cleanser resulted in a 50% reduction in the rate of blood stream infections. The same study also reported a significant reduction of inguinal colonization with all gram-positives, MRSA, VRE, yeast and gram-negatives.

Each disposable washcloth rapidly reduces bacteria on the skin that can cause infection. Unlike other CHG solutions, it's designed to stay on the skin. So it provides maximum antimicrobial persistence against a wide variety of microorganisms. Sage Antiseptic Body Cleanser makes it easier to address skin decolonization.

Enhance your infection-prevention efforts today.
Call your Sage Products representative at 1-800-323-2220.

For more information about Sage Antiseptic Body Cleanser visit: www.sageproducts.com/canada/chg
Update: Catheter-related bloodstream infection rates in relation to clinical practice and needleless device type 156
Infection prevention and control learning preferences of nurses sampled at a teaching hospital 165
2009 Education Conference ____________________________ 180
Industry membership changes ________________________ 184

DEPARTMENTS:
Editor's Message ____________________________________ 150
President’s Message ____________________________________ 152
Message de la Présidente _______________________________ 154
Association News _________________________________ 178
Reach Our Advertisers ________________________________ 204

VISION
CHICA-Canada will lead in the promotion of excellence in the practice of infection prevention and control.

MISSION
CHICA-Canada is a national, multidisciplinary, voluntary association of professionals. CHICA-Canada is committed to improving the health of Canadians by promoting excellence in the practice of infection prevention and control by employing evidence-based practice and application of epidemiological principles. This is accomplished through education, communication, standards, research and consumer awareness.

The Canadian Journal of Infection Control is the official publication of the Community and Hospital Infection Control Association (CHICA)-Canada. The Journal is published four times a year by Craig Kelman & Associates, Ltd. and is printed in Canada on recycled paper. Circulation 3000.

©2008 Craig Kelman & Associates Ltd. All rights reserved. The contents of this publication, which does not necessarily reflect the opinion of the publisher or the association, may not be reproduced by any means, in whole or in part, without the written consent of the publisher.

ISSN - 1183 - 5702
Indexed/abstracted by the Cumulative Index to Nursing and Allied Health Literature, SilverPlatter Information Inc. and the International Nursing Index (available on MEDLINE through NLM MEDLARS system).

The Canadian Journal of Infection Control is a “Canadian periodical” as defined by section 19 of the Canadian Income Tax Act. The deduction of advertising costs for advertising in this periodical is therefore not restricted.

SUBSCRIPTIONS
Subscriptions are available from the publisher at the following rates:
All Canadian prices include GST. Prices are listed as personal/institutional.
Canada: $30/$38 (GST # 100761253); USA (in US funds): $28/$36;
Other countries: $45/$60.
CHICA–CANADA
2008 Board of Directors

Executive Officers

President
Marion Yetman, RN, BN, MN, CIC
Provincial IC Nurse Specialist
Government of Newfoundland Labrador
Dept. of Health & Community Services
1410 West Block, Confederation Bldg
PO Box 8700
St John’s NL A1B 4J6
Tel: 709-729-3427
Fax: 709-729-7743
Marion.Yetman@gov.nl.ca

President-elect
Cathy Munford, RN, CIC
Infection Control Practitioner
Victoria General Hospital
1 Hospital Way
Victoria BC V8Z 6R5
Tel: 250-727-4021
Fax: 250-727-4003
cathy.munford@shaw.ca

Past President
Joanne Laalo, RN, BScN, CIC
Infection Control Consultant
Central South Infection Control Network
56 Governor’s Road
Dundas ON L9H 5G7
Phone: 905-627-3541 x 2484
Fax: 905-627-6474
jlaalo@cmh.org

Secretary/Membership Director
Bern Hankinson, RN, BN, CIC
Infection Prevention & Control Prac
Wetaskiwin Hospital
6910 47th Street
Wetaskiwin AB T9A 3N3
Tel: 780-361-4398
Fax: 403-361-4107
bhankinson@dthr.ab.ca

Director of Finance
Cynthia Plante-Jenkins, MLT, BScMLS(C), CIC
Clinical Informatics Specialist - Lab
Trillium Health Centre
100 Queensway W
Mississauga ON L5A 1B8
Phone: 905-849-7580 ext.2927
Fax: 905-849-7772
cplante-jenkins@thc.on.ca

Director, Standards & Guidelines
Bonnie Henry, MD, MPH, FRCPC
Physician Epidemiologist
BC Centre for Disease Control
655 West 12th Ave
Vancouver BC V5Z 4R4
Phone: 604-660-1823
Fax: 604-660-0197
bonnie.henry@bccdc.ca

Physician Director
Dick Zoutman, MD, FRCPC
Medical Director, IC Service
Kingston General Hospital
76 Stewart Street
Kingston ON K7L 2V7
Phone: (613) 549-6666 Ext. 4015
Fax: (613) 549-2513
zoutman@kg.h.kari.net

Membership Services Office
Executive Administrator/Conference Planner
Gary Hansen, BA
PO Box 46125 RPO Westdale
Winnipeg MB R3R 3S3
Phone: 204-897-5990/866-999-7111
Fax: 204-895-9595
chicacanada@mts.net

Deliveries only:
67 Bergman Crescent
Winnipeg MB R3R 1Y9

Administrative Assistant
Kelli Wagner
kelli_wagner@mts.net

Directors

Director of Education
Donna Morales, PhD
Memorial University School of Nursing
300 Prince Philip Drive
St John’s NL A1B 3V6
Tel: 709-777-6527
Fax: 709-777-7037
moralesjo@mun.ca

Director, Programs & Projects
Karen Clinker, Med, BScN, CCWH, CIC
Infection Control Consultant
Northwestern Ontario IC Network
100 Casimir Ave, Suite 217, Box 116
Dryden ON P8N 3L4
Tel: 807-223-4408
Fax: 807-223-4139
clinkerk@tbh.net

Other Positions

Archivist
Mary LeBlanc, RN, BN, CIC
RR#2, Civic #11763
Tyne Valley, PE C0B 2C0
nananandpapa@route2.pe.ca

Web Master
Shirley McDonald, ART, CIC
RR 3, 4759 Taylor-Kidd Blvd
Bath ON K0H 1G0
Tel: 613-389-9810
Fax: 613-389-8488
chicawebmaster@mts.net

Distance Education Coordinator
Karen Dobbin-Williams, RN, BN
28 Dalhousie Crescent
Mount Pearl NL A1N 2Y4
Tel: 709-745-7341
kdobbin@mun.ca

Clinical Editor
Canadian Journal of Infection Control
Pat Paiakowski, RN, BScN, CIC
Regional Coordinator
Northwestern Ontario IC Network
289 Munro Street
Thunder Bay ON
P7A 2N3
Tel: 807-683-1747
Fax: 807-683-1745
piaskowp@tbh.net

Professional Agents

Legal Counsel
Sidney Troister/S. Fay Sulley
Torkin, Manes and Cohen
151 Yonge Street, Suite 1500
Toronto ON M5C 2W7
Phone: (416) 777-5419
Fax: (416) 863-0305

Auditor
Philip Romanuk CA
Stefansson Lee Romanuk
1151 Portage Avenue
Winnipeg MB R3G 0S9
Phone: (204) 775-8975
promanuk@elrca.ca

Membership Services Office
MEMBERSHIP SERVICES OFFICE
Executive Administrator/Conference Planner
Gary Hansen, BA
PO Box 46125 RPO Westdale
Winnipeg MB R3R 3S3
Phone: 204-897-5990/866-999-7111
Fax: 204-895-9595
chicacanada@mts.net

Deliveries only:
67 Bergman Crescent
Winnipeg MB R3R 1Y9

Administrative Assistant
Kelli Wagner
kelli_wagner@mts.net
Try Sterillium® Rub
and your hands will
love you for it.

A treat for tender hands
Unlike other surgical hand antiseptics, Sterillium Rub leaves hands feeling soft and smooth, not greasy or sticky. It dries quickly and leaves no buildup—allowing quicker, easier gloving—and it won’t irritate or dry out your skin.

Convenient, hygienic delivery system
Sterillium Rub is available in a state-of-the-art touchless dispenser—a good choice if you’re tired of foot pedals that break easily, get dirty, or are hard to reach. A two-minute application of this FDA-compliant antiseptic provides immediate and persistent bactericidal activity.

Feel the difference. Try Sterillium Rub in your OR.

Contact your Medline representative or call 1-800-396-6996.

©2007 Medline Industries, Inc. Medline is a registered trademark of Medline Industries, Inc. Sterillium is a registered trademark of Bode-Chemie GmbH.
Infection control professionals (ICPs) in some provinces in Canada are finding themselves providing infection control surveillance data for certain HAIs for public reporting by their facilities. Whether this is a growing trend in Canada will remain to be seen.

Beyond the immediate and obvious need to provide accurate data what does this mean for the ICP? For ICPs involved in public reporting their infection control surveillance data is no longer just a matter of discussion or review in their own facility. Typically this data is shared only with the infection prevention and control (IPAC) committee and other key individuals and committees within the facility. Now, with public reporting, this data will be viewed by a much broader audience and potentially, through web-based reports, by the world.

Accountability for this reported data, however, starts at the top. The board and CEO are ultimately accountable for the outcomes. The ICP is one member of the health care team with a very important role. However, the ICP and the IPAC committee cannot affect the rates, without the support and cooperation of the governance and management of their facility. Inadequately resourced IPAC programs and facilities with limited support for other basic infrastructure such as housekeeping, facilities management, and laboratory will all negatively impact these rates.

With this new role, the ICP is now at the forefront of a trend which may impact their facility and the IPAC program. When reported rates are high there may be increased public and media scrutiny of the facility and their IPAC program.

The APIC/CHICA/CBIC infection prevention, control and epidemiology: professional and practices standards, published in the last issue of CJIC, are now more important than ever in helping ICPs to define their role. All ICPs should become familiar with these standards and measure their own role and performance in light of them. Whether our surveillance data will be public is not what is important. What is important is how we as individual ICPs and as a profession respond to this new challenge.

As stated in the CHICA-Canada mission statement:
“CHICA—Canada is committed to improving the health of Canadians by promoting excellence in the practice of infection prevention and control by employing evidence based practice and application of epidemiological principles. This is accomplished through education, communication, standards, research and consumer awareness.”

“The ICP is now at the forefront of a trend which may impact their facility and the IPAC program.”
Capping the spread of BSIs

Child-resistant packaging of oral prescription drugs has saved the lives of approximately 900 children over a 27 year span.*

Catheter-related blood stream infections (CRBSIs) have an estimated 12-25% mortality rate.† BD combats blood stream infections (BSIs) with an integrated IV therapy system. When used together, BD Nexiva™ Closed IV Catheter System, BD Q-Syte™ Closed Luer Access and BD Posiflush™, BD Normal Saline Flush Syringes reduce the potential of contamination and risk of BSIs while increasing efficiencies. BD is committed to protecting patients against BSIs with innovative products. To learn more call: 1-800-268-5430

BD, BD Logo and all other trademarks are the property of Becton, Dickinson and Company. © 2008 BD
Healthcare associated infections (HAIs) cause 9,000-12,000 deaths each year in Canadian hospitals. In addition it is estimated that 250,000 persons suffer from HAIs annually in Canada. The infections have serious implications not only in terms of pain and suffering but in relation to the patients’ ability to carry on their everyday activities. Consequences of infections can result in significant interruptions in the patient’s family and work life.

This call to action has been answered by CHICA-Canada. Last year in collaboration with colleagues from the Canadian Foundation for Infectious Diseases (CFID), the Association of Medical Microbiology and Infectious Disease (AMMI) Canada, the Canadian Association for Clinical Microbiology and Infectious Diseases (CACMID), the International Centre for Infectious Diseases (ICID) and industry partners, CHICA-Canada participated in a National Infectious Disease Day (NIDD) in Ottawa. On October 23, 2007 this group (the NIDD coalition) met with Members of Parliament (MPs). The purpose was to make MPs aware of the impact of HAIs on Canadians and to solicit their help in getting more funding to address HAIs.

This year the NIDD coalition is working on a different approach to address HAIs in Canada. The coalition is focusing on an awareness campaign which will include press releases and meetings with potential MPs, those running for public office in the next election. The key messages that have been developed are:

• An overview of the problem – the impact of HAIs.
• The action that is required – there needs to be an investment of $200 million in funding to address the problem of HAIs.
• Vision – this investment would lessen the burden on Canadian both in terms of reduced pain and suffering from HAI and reduced financial burden on Canada’s health care system.

CHICA-Canada is requesting your help in bringing these messages to your local federal representative. Details of the initiative can be found on the NIDD website (www.nidd.ca) and on CHICA-Canada’s website (www.chica.org). We encourage you to visit these websites and become familiar with the issues and the action that we are supporting.
the next generation
of sterility assurance
is here.

Introducing the new Class 6 Verify® SixCess™ Challenge Packs and Indicators

> Reduce the wait; immediate release of all loads
> Reduce the risk; eliminate “blind” release
> Reduce the work; no readers or incubation required

For more information, contact STERIS Canada Inc. at 1.800.661.3937 or visit www.steris.com
MESSAGE DE LA PRÉSIDENTE

**Infections dans les soins de santé : appel à l’action**

Les infections directement liées aux soins de santé provoquent de 9 000 à 12 000 décès chaque année dans les hôpitaux canadiens. De plus, on estime que, chaque année, 250 000 personnes contractent de ce genre d’infections au Canada. Les infections ont de graves conséquences, non seulement sur le plan de la douleur et de la souffrance mais aussi sur celui de la capacité des patients à poursuivre leurs activités quotidiennes. Elles peuvent entraîner d’importantes perturbations dans la vie professionnelle et familiale des patients.

Cet appel à l’action a trouvé écho au sein de l’Association pour la prévention des infections à l’hôpital et dans la communauté-Canada (CHICA-Canada). L’année dernière, en collaboration avec des collègues de la Fondation canadienne des maladies infectieuses (FCMI), de l’Association pour la microbiologie médicale et l’infectiologie Canada (AMMI-Canada), de l’Association canadienne de microbiologie clinique et des maladies infectieuses, de l’International Centre for Infectious Diseases (ICID) et de partenaires sectoriels, CHICA-Canada a pris part à une Journée nationale des maladies infectieuses (NIDD) à Ottawa. Le 23 octobre 2007, ce groupe (la coalition de la NIDD) a tenu une réunion avec des députés, qui visait à sensibiliser ces derniers à l’incidence des infections dans les soins de santé sur les Canadiens et à solliciter leur aide pour obtenir davantage de fonds afin de régler ce problème.

Cette année, la coalition de la NIDD s’efforce d’élaborer une approche différente de cette question au Canada. Elle concentre son attention sur une campagne de sensibilisation comprenant des communications de presse et des rencontres avec des candidats et candidates à des postes de députés au terme de la campagne électorale en cours. Les principaux messages élaborés sont les suivants :

- un aperçu du problème – l’incidence des infections dans les soins de santé;
- les mesures nécessaires – la nécessité d’effectuer un investissement de 200 millions $ afin de régler le problème des infections;
- une vision – cet investissement réduirait le fardeau des Canadiens tant sur le plan de la diminution de la douleur et de la souffrance dues à ces infections que sur celui du financement du système de soins de santé au Canada.

CHICA-Canada sollicite votre aide pour transmettre ces messages à votre député fédéral local respectif. Vous pourrez trouver davantage de détails sur cette initiative sur le site Web de la NIDD (www.nidd.ca) et celui de CHICA-Canada (www.chica.org). Nous vous encourageons à vous rendre sur ces sites et à vous familiariser avec les enjeux et les mesures qui bénéficient de notre appui.

« CHICA-Canada sollicite votre aide pour transmettre ces messages à votre député fédéral local respectif. »

Parce que vous êtes en contact quotidien avec vos clients, il est recommandable de prendre toutes les précautions possibles pour ne pas transmettre les germes et les infections.

C’EST EVIDENT!

Depuis 1968, le système “Glo Germ™” est utilisé pour enseigner des techniques efficaces de nettoyage et lavage. La poudre et la lotion “Glo Germ™” contiennent des microbes inerts et inoffensifs, qui réagissent quand ils sont exposés au clairage ultra-violet standard.
NOW you hold the power to fight for your patients

INTRODUCING

V·Link™
Luer Activated Device

VitalShield
Protective Coating

The first antimicrobial IV connector

Kills on average 99.9% or more of specific common pathogens known to cause catheter-related bloodstream infections (CR-BSIs)†

†These in vitro test results of typical devices have not been shown to correlate with a reduction in infections.

Visit www.baxter.com

The antimicrobial agent is not intended to be used as a treatment for existing infections. Rx Only.
For safe and proper use of this device, please refer to the complete instructions for use.

Baxter, Committed to a Safer Healthcare Environment, V·Link, and VitalShield are trademarks of Baxter International Inc
Baxter Healthcare Corporation, 4 Robert Speck Parkway, Suite 700, Mississauga, ON, L4Z 3Y4 www.baxter.com 213236C 0308
**Update: Catheter-related bloodstream infection rates in relation to clinical practice and needleless device type**

**ABSTRACT**
Catheter-related bloodstream infection (CR-BSI), the third most common healthcare-associated infection (HAI) in the intensive care unit, is a significant issue for infection prevention and control professionals. CR-BSIs result in significant increases in morbidity, mortality, length of hospital stay and financial costs and therefore must be regarded as a failure in patient care. Among the factors affecting CR-BSI rates are the type of needleless access device, access device disinfection methods, compliance with infection prevention and control procedures, clinician training and ongoing education, the number of individuals accessing the device, and patient characteristics. Consistent implementation of institutional infection prevention and control protocols has demonstrated a reduction in CR-BSI incidence. Recent studies in the literature on needleless access devices indicate mechanical valve access devices appear to be associated with an increased BSI rate compared to split septum access devices; however, the reasons have not been completely elucidated. Reduction in CR-BSI rates depends on adherence to best practice in infection prevention; selection of appropriate needleless intravenous (IV) infusion systems; and routine BSI surveillance, with timely dissemination of data within the institution. This article discusses the links amongst CR-BSIs and adherence to aseptic techniques for catheter insertion, access device disinfection and maintenance, and differences in needleless access device technologies. A review of patient-related factors is beyond the scope of this article.

**INTRODUCTION**
Catheter-related bloodstream infection (CR-BSI) is a significant issue for infection prevention and control professionals (ICPs). After ventilator-associated pneumonia and catheter-related urinary tract infection, CR-BSI is the third most common healthcare-associated infection (HAI) reported from intensive care units (ICUs). The Centers for Disease Control and Prevention (CDC) estimates approximately 250,000 CR-BSIs occur annually in American hospitals, resulting in a 12 to 25% attributable mortality and a $25,000 USD marginal cost per episode. Approximately 80,000 episodes occur in ICUs, at a cost of $34,508 to $56,000 USD per infection. The number of CR-BSIs occurring in areas outside ICUs is not widely reported. This article discusses impact of clinical practice and type of needleless access device on CR-BSI rates and contamination.

Needleless access devices were developed in the late 1980s to reduce the risk of needlestick injuries to healthcare workers. Before needleless access devices were introduced, healthcare workers administered medications or additional fluids by using a needle to puncture a rubber diaphragm (PRN adapter) integrated into the intravenous (IV) tubing. Needleless access devices allow administration of IV fluids without the use of needles while maintaining a closed system. They may be either a stand-alone device or a device integrated into the IV administration set. Needleless access devices have evolved over the years in an effort to address safety and infection risks. The influence of patient-related factors, such as severity of illness, underlying disease, and immune status, is beyond the scope of this article.
Clinical practice factors which contribute to BSI include the CVC insertion site, technique, access and management. Problems associated with catheter and access site management include improper disinfection, improper flush, improper clamping, frequency of manipulation, failure to replace access devices per institutional protocol, poor catheter site dressing regimen, and urgent catheter placement (Figure 1). The frequency of user compliance with established protocols is unknown.

A variety of protocols and interventions have been developed to reduce BSI incidence by addressing clinical practice factors. The Central Line Bundle is an example of a standardized, research-based set of interventions introduced by the Institute for Health Improvement and the Canadian Patient Safety Institute to address these issues. The key components of the Central Line Bundle consist of hand hygiene; maximal sterile barrier precautions for insertion; 2% chlorhexidine with 70% alcohol skin antisepsis; optimal catheter site selection (in the adult population, the subclavian vein is the preferred site for non-tunnelled catheters); and daily review of line necessity, with prompt removal of unnecessary lines. Documented evidence indicates a reduction in CR-BSI rates when all components of the bundle are implemented.

Other approaches, following similar principles, have also been shown to be effective. The Pittsburgh Regional Healthcare Initiative (PRHI), in collaboration with the CDC, developed a hospital-based initiative to prevent CR-BSIs in ICUs in South-western Pennsylvania. Over a four-year period, the PRHI achieved a 68% decrease in BSI rates per 1000 catheter days, from 4.31 to 1.36 (p < .001). Key components of the initiative included promotion of education about CR-BSIs and preventive strategies, evidence-based catheter insertion techniques, a standardized list of contents for catheter insertion kits to support recommended techniques, standardized tools for recording adherence to recommended techniques, measurement of CR-BSI rates, and confidential distribution of data to participating institutions.

In 2002, a surgical ICU in Baltimore used a similar intervention to reduce CR-BSIs. The rate decreased from 11.3 per 1000 catheter days during the first quarter of 1998 to 0 per 1000 in the fourth quarter of 2002. Promoted infection prevention strategies were not new, but the data demonstrate the effectiveness of consistency and coordination in infection prevention and control practices to reduce catheter-associated events, including BSIs.

**Access Devices and Bloodstream Infection**

In addition to clinical practice issues, needleless access device-related factors may be important contributors to BSIs. Access device-related factors include the type of catheter (tunnelled or non-tunnelled) and the securement method (Table 1). Access devices with a gap around the plunger may allow bacterial colonization; an opaque housing hides incomplete flushing of media-based fluids; and internal mechanisms can obscure the fluid path (Figure 2). In several institutions, an increase in BSI rates has been linked temporally to changes in needleless access devices from split septum (SS) to mechanical valve (MV) devices.

In June 2002, Hall et al reported a 61% increase in the primary HAI BSI rate per 1000 catheter days from analyzed data. The rate increased significantly from 2.2 (January-May 2002) to 3.5 per 1000 catheter days (June-December 2002) (p = .00003). This increase was temporally associated with the hospital-wide introduction of a new MV needleless infusion system in late May 2002. Organisms identified included both common skin flora and pathogenic strains. Retrospective analysis identified both contamination rates and true BSI rates before and during the outbreak. Contamination was defined as isolation of a common skin organism from only one of two or more sets of blood cultures taken from different sites over a five-hour period. Any other positive cultures were classified as true BSIs. Contamination rates for CVC cultures increased from 1.7 to 6.5% (p < 10^-7), and positive cultures increased from 6.1 to 11.6% (p < 10^-7). Hall et al concluded the increased...
CVC contamination rate coincided with implementation of the MV needleless access device, which might be more apt to become colonized with bacteria13.

In September 2003 Karchmer et al found a significant (p = .02) increase in ICU BSIs and evaluated various factors in the search for a cause. Neither CVC insertion techniques nor care and maintenance could explain the observed increase. A nursing practice survey found 31% of nurses did not disinfect the valve device before accessing the system. Documented improvements in technique did not resolve the issue. Quantitative cultures were performed using blood samples drawn from the normally discarded initial syringe pull back. Microbiological culturing of 226 blood samples from 83 patients identified a 17% positive culture rate. Of patients with a positive sample, 12% had a BSI with the same organism. Further investigation determined the institution had switched to a new valved needleless access device coincident with the time the increase in BSIs began. Karchmer et al concluded the BSI rate increase was likely due to both true and pseudo-bacteremia related to the access device design and use14.

In 2004 in a long-term acute-care hospital, Salgado et al compared infection rates during the 24-month period after introduction of a needleless MV access device to rates in the preceding 24-month period, when an SS access device was used15. During the study period, protocols for CVC care were unchanged; the surface of the MV needleless access device was disinfected with 70% isopropyl alcohol by rubbing vigorously for 3 to 5 seconds; and the IV tubing and needleless access device were changed.
every 96 hours. The tubing was changed daily if a blood product or parenteral nutrition was administered. Salgado et al found a sustained and significantly increased BSI rate (5.95/1000 catheter days, p < .001) associated with the use of the MV access device, compared with the period during which the SS access device was in use (1.79/1000 catheter days). Repeated education for nurses on correct MV use did not lower the rate. Based on their data and other literature reports, Salgado et al concluded MV needless access device design, recommended disinfection protocols, or both, may be inadequate for safe use in some patient populations.

In 2005, in response to a perceived increase in BSI rate coincident with conversion from an SS to an MV access device, Field et al conducted an audit of CR-BSI rates in an Australian haematology/oncology unit. The retrospective audit included all patients who had Hickman catheters placed during hospitalization in the hematology/oncology unit between July 1, 2004 and June 30, 2005. Of the 32 confirmed CR-BSIs during the study period, 20 occurred during the MV period (November 1, 2004 until March 31, 2005) and 12 during the SS period (before and after MV period). Rates were consistent across patient disease site subgroups and catheter types. Analysis found a BSI rate of 2.6/1000 catheter days during the SS period and 5.8 during the MV period (p = .031). After the study period, continued monitoring found a BSI rate of 2.3/1000 catheter days (July 31-December 31), similar to the rate during the SS study period. No additional clusters of BSI cases were noted. Consistent with other reports, the findings of this study suggest colonization of MV connectors may be associated with increased CR-BSI rates.

Jarvis et al convened peer meetings in June and October 2004 to discuss BSI rate increases associated with the switch from SS to MV needleless access devices, to identify contributing factors, and to gain a better understanding of the problem. ICPs shared data gathered from five hospitals with documented BSI increases. Reasons for switching to MVs included safety (reducing needle-stick injuries), change in IV systems, concerns about future availability of SS access devices, a desire for neutral- or positive-pressure access devices, the potential to reduce intravascular access device occlusion, and better visibility of the hub area with some MVs. The increase in BSI rate (Figure 3) continued despite staff re-education about aseptic technique and use of other appropriate infection prevention and control practices. Intensive educational efforts regarding the use and care of needleless access devices may not reduce BSI rates associated with MVs. At the three hospitals that discontinued MV use, the BSI rate decreased to pre-MV levels. The BSI rate did not, however, return to baseline at the two hospitals where MV use continued.

Figure 2. Cross-sections of needleless access devices: a) split-septum (SS); b) mechanical valve (MV); and c) MV with positive fluid displacement.

![Image](image-url)
ICPs have voiced concerns about serious outcomes potentially associated with needleless access devices for several years. Despite various recent claims, the dominance of any needleless access device design has not been conclusively proven. Current studies vary widely in scope; design, duration, and limitations; and scientific rigor. Long-term outcomes have not been discussed. Until more evidence is offered regarding design impact on risk of infection, none of the currently available needleless access devices can truly assert dominance. In reality, the 2002 Healthcare Infection Control Practices Advisory Committee (HICPAC) Guidelines for the Prevention of Intravascular Catheter-Related Infections maintain when the entire needleless intravascular catheter system is used according to manufacturer recommendations, it does not substantially affect CR-BSI incidence. All data supporting this statement, which was published in 2002, were published not later than 2000; more current data have been discussed in this article.

Newer access devices may be associated with reduced infection rates and ease of use. With no internal moving parts, SS needleless access devices have a structure similar to proven traditional injection sites and allow needleless access with a blunt cannula. In 2005, Adams et al evaluated \textit{(in vitro)} an SS needleless access device to determine its potential for microbial contamination. The study compared needleless access devices that had been activated up to 70 times. The outer surfaces of 50 SS devices were inoculated with \textit{Staphylococcus epidermidis}. The compression seals were disinfected by firm application of 70\% isopropyl alcohol swabs and rotation through 360° five times. The needleless access devices were then flushed with 0.9\% sterile saline. Finally, the flush solutions were cultured. Ninety-six percent (48/50) of the flush solutions remained sterile. An additional 25 SS devices were challenged using 0.9\% sterile saline-filled syringes whose external luer tips had been inoculated with \textit{S. epidermidis}. The needleless access devices were flushed, and the flush effluents were cultured. Microorganisms were detected on both the syringe tip and the outer surface of the SS devices, but no microorganisms passed through the access septum. Adams et al concluded the access device septum prevented any microorganisms on the external luer surface of the syringe from entering the fluid path.

Data from Jarvis et al (16).

BSI bloodstream infection; ICU intensive care unit; MV mechanical valve; SS split septum.

**CONCLUSION: SURVEILLANCE AND CLINICAL PRACTICE**

CR-BSIs significantly increase morbidity and mortality and must be regarded as a failure in patient care. Many factors affect CR-BSI rates, including, but not limited to, the type of needleless access device used, the patient characteristics, the method of access device disinfection, adherence to institutional infection prevention and control protocols, clinician competence, and the number of individuals accessing the device.

The association of CR-BSIs with increased morbidity, mortality, length of hospital stay, and associated costs highlights the importance of BSI surveillance. This includes monitoring long-term trends, assessing the impact of any IV system changes, and monitoring adherence to protocols by clinicians. Furthermore, an increase in BSI rates should prompt an evaluation of potential causes.

There are available data on BSI rates associated with changes in needleless IV access devices. As existing reports are primarily from the ICU setting, information from other high-use areas in acute care hospitals, long-term care facilities, home health care and from multicentre investigations would also be beneficial. Long-term outcomes should be assessed. The current design and/or recommended protocols for disinfection of needleless access devices may not be adequate for clinical use in some populations. Research comparing the effect on patient outcome of MV technologies with other closed-system technologies, including SS access devices, is needed.

Needleless access devices present both advantages and disadvantages, and will only be as safe and reliable as the person using them. Pending definitive evidence highlighting the domination of one device type over others, health care workers must continue to moni-
In Canada, an estimated 220,000 infections acquired in healthcare facilities and 8,000 deaths attributable to these infections occur annually.\(^{(1)}\)

**AMD infection control products help to reduce infections by between 52\(^{(3)}\) and 91\(^{(2)}\)**

A highly effective, low cost solution
- Broad spectrum effectiveness and proven effective at preventing dressing colonization against MRSA, VRE & Acinetobacter Baumannii and many more
- No known resistance
- Works within and through the dressing
- Gentle to healthy cells

\(^{(1)}\) Zoutman, DE, Ford DB, Bryce E et al; The state of infection surveillance and control in Canadian Acute Care Hospitals; Am J Infect Control, 2003; 31:266-73.

\(^{(2)}\) The Reduction of Vascular Surgical Site Infections with the Use of Antimicrobial Gauze Dressing; Robert G. Penn, MD, Sandra K. UyHial, RN, MSN, CIC, Sylvia Roberts, RN, Susan Miller, RN, BSN, CIC. Dept. of Epidemiology, Nebraska Methodist Hospital, Omaha, NE, USA. Observation of Nosocomial Surgical Site Infections with Utilization of Antimicrobial Gauze Dressing in an Acute Care Setting; Mary Jo Beneke, RN BS, CWOCN, Josephine Daniel, RN BSN MA, CIC. Yuma Regional Medical Center, Yuma, AZ.

\(^{(3)}\) Observation of Nosocomial Surgical Site Infection Rates with Utilization of Antimicrobial Gauze Dressing in an Acute Care Setting; Mary Jo Beneke, RN BS, CWOCN; Josephine Daniel, RN, BSN, MA, CIC. Yuma Regional Medical Center, Yuma, AZ.
tor needleless access devices, evaluate outcomes and CR-BSI rates, and attempt to better address potential for user error within all practice settings.

Additional research may help to resolve many unanswered questions, including the following: Why are MV needleless access devices associated with higher infection and contamination rates? Are all MV needleless access devices associated with a similar risk of BSI? Are simple access devices more resistant to infection than complex access devices if adherence to aseptic technique is imperfect?

The keys to improvement in CR-BSI rates include adherence to best practices in infection prevention and control; selection of appropriate needleless access devices; and routine surveillance, including timely dissemination of data, both within the institution and to other ICPs. Finally, it is important for healthcare facilities to be aware of the possible association between any new technology and HAI.

PRACTICE POINTS

1. It is desirable to perform ongoing BSI surveillance and monitor adherence to aseptic technique.
2. When changing access devices, it is important to monitor the impact of such changes on BSI rates.
3. Ongoing education on best practices and monitoring of adherence is recommended for all clinicians who access the needleless IV system.

REFERENCES

IN THE WAR AGAINST INFECTION, CONSIDER YOURSELF ARMED

For Surface Care, Trust Sani-Cloth® Plus Germicidal Disposable Cloth

Sani-Cloth® Plus is a hospital-grade disinfectant specifically formulated for use on hard non-porous environmental surfaces found throughout healthcare.

- Kills Mycobacterium bovis BCG (Tuberculosis), Methicillin resistant Staphylococcus aureus (MRSA), Escherichia coli (E. coli) O157:H7 and HCV (Hepatitis C Virus)
- Cleans and disinfects
- Unique Deep Well Lid provides ample space to store and access next wipe
- Convenient quick pull canister and individual packet options

For information on Sani-Cloth® Plus contact your distributor, visit www.pdipdi.com or call 800-999-6423.
Hand Hygiene Saves Lives
It's in your hands to break the chain of infection.

Isagel 70%
Alcohol Ethyl

Each year, nosocomial infections affect thousands of patients across Canada. The cost of treating this hidden epidemic is staggering.

Evidence proves Isagel kills

<table>
<thead>
<tr>
<th>Organism</th>
<th>Percent Reduction in 15 seconds</th>
<th>Log Reduction in 15 seconds</th>
<th>Percent Reduction in 30 seconds</th>
<th>Log Reduction in 30 seconds</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gram Positive Bacteria</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E. faecium (VRE)</td>
<td>&gt;99.99</td>
<td>&gt;5.99</td>
<td>&gt;99.99</td>
<td>&gt;5.46</td>
</tr>
<tr>
<td>Staph aureus</td>
<td>99.96</td>
<td>3.46</td>
<td>99.99</td>
<td>3.96</td>
</tr>
<tr>
<td>Staph aureus (MRSA)</td>
<td>99.96</td>
<td>3.36</td>
<td>&gt;99.94</td>
<td>&gt;3.19</td>
</tr>
<tr>
<td>Staph epidermidis</td>
<td>99.97</td>
<td>3.48</td>
<td>99.96</td>
<td>3.46</td>
</tr>
<tr>
<td>Staph haemolyticus</td>
<td>99.93</td>
<td>3.16</td>
<td>&gt;99.96</td>
<td>&gt;3.40</td>
</tr>
<tr>
<td>Strep pyogenes</td>
<td>&gt;99.95</td>
<td>3.34</td>
<td>&gt;99.99</td>
<td>&gt;4.37</td>
</tr>
<tr>
<td><strong>Gram Negative Bacteria</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bacteroides fragilis</td>
<td>99.90</td>
<td>2.99</td>
<td>99.97</td>
<td>3.48</td>
</tr>
<tr>
<td>Haemophilus influenzae</td>
<td>&gt;99.99</td>
<td>&gt;5.72</td>
<td>&gt;99.99</td>
<td>&gt;5.76</td>
</tr>
<tr>
<td>Klebsiella pneumoniae</td>
<td>99.85</td>
<td>2.82</td>
<td>&gt;99.97</td>
<td>&gt;5.51</td>
</tr>
<tr>
<td>Proteus mirabilis</td>
<td>&gt;99.99</td>
<td>&gt;5.29</td>
<td>&gt;99.99</td>
<td>&gt;6.15</td>
</tr>
<tr>
<td>Salmonella typhimurium</td>
<td>&gt;99.97</td>
<td>&gt;3.58</td>
<td>&gt;99.99</td>
<td>&gt;6.30</td>
</tr>
<tr>
<td>Shigella dysenteriae</td>
<td>&gt;99.99</td>
<td>&gt;6.71</td>
<td>&gt;99.99</td>
<td>&gt;6.82</td>
</tr>
<tr>
<td><strong>Anaerobic Bacteria</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C. Difficile</td>
<td>&gt;99.68</td>
<td>&gt;2.49</td>
<td>&gt;99.98</td>
<td>&gt;3.64</td>
</tr>
<tr>
<td><strong>Fungi</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Candida albicans</td>
<td>99.97</td>
<td>3.52</td>
<td>&gt;99.99</td>
<td>&gt;4.34</td>
</tr>
<tr>
<td><strong>Viruses</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Herpes Simplex Type I</td>
<td>&gt;99.99</td>
<td>5.3</td>
<td>&gt;99.99</td>
<td>5.3</td>
</tr>
<tr>
<td>Herpes Simplex Type II</td>
<td>&gt;99.9</td>
<td>3.7</td>
<td>&gt;99.99</td>
<td>3.7</td>
</tr>
<tr>
<td>Rotavirus</td>
<td>&gt;99.9</td>
<td>3.9</td>
<td>&gt;99.99</td>
<td>3.9</td>
</tr>
</tbody>
</table>
Infection prevention and control learning preferences of nurses sampled at a teaching hospital

Note: This study was based out of the Toronto General Hospital site of the University Health Network in Toronto, Ontario.

Authors:
Siu Mee Cheng, MHSc., BASc., CHE
President,
Point Consulting Services
(Former Corporate Quality Improvement Manager, University Health Network)

Melanee Eng-Chong, M.L.T., B.Com., CIC
Infection Control Co-ordinator,
Sunnybrook Health Sciences Centre
and
Secretary of the Toronto and Area Professionals in Infection Control (TPIC) chapter of the Community and Hospital Infection Control Association (CHICA) – Canada
(Former Infection Control Practitioner, University Health Network)

Brian Rawson, BSc., BASc.
Health Promotion Officer,
Region of Peel – Public Health Department
(Former Student Research Investigator, University Health Network)

Author Correspondence:
Brian Rawson
2101-10 Hogarth Avenue
Toronto, ON M4K 1J9
(416) 463-4405
brianrawson_1975@yahoo.ca

ABSTRACT
A pilot study was conducted within the medical-surgical intensive care unit (MSICU) of the Toronto General Hospital site of the University Health Network during the winter/spring (March-June) of 1999 to examine nurses’ learning preferences relevant to infection prevention and control (IPAC).

The majority of the nurses sampled indicated a preference for face-to-face infection prevention and control education (seminars). Such seminars were preferred on an annual basis by most respondents. Common preferences for paper-based learning formats were observed to be portable flash cards, packages with text and pictures and reference manuals. Such paper-based modalities could be considered in concert with infection control seminars; possibly to serve as easily accessible reminders within hospital units. Although not observed in this study, exploring differences in learning preferences across various demographic characteristics of nurses (e.g. years of experience) could be valuable.

It is important to assess the specific IPAC learning needs of nurses before designing educational interventions. Assessing the effectiveness of learning modalities in improving infection control practices is advised. The practicality of nurse participation in various educational initiatives also must be considered, as barriers to nurse participation in continuing education have been noted. Furthermore, organizational commitment to infection prevention/safety should be reinforced through future training opportunities for health care workers (HCWs).

Challenges with the application of new technology to educational modalities have been cited, which bears relevance to these findings. These observations are presented in order to inform infection control training of nurses in the post-SARS milieu of health care provision in Canada.

INTRODUCTION
The importance of preventing hospital/healthcare-associated infections has been particularly emphasized within the post-Severe Acute Respiratory Syndrome (SARS) environment of health care provision in Canada. Heightened attention and commitment towards patient safety has also emerged as an important component of Canadian health care. Adverse events (AEs) are an accepted indicator of patient safety and are defined as “unintended injuries or complications that are caused by health care management” and include hospital-acquired infections. AEs can lead to death, disability (at time of discharge) or extended hospitalization. Approximately 7.5 per cent of adult hospital admissions in Canada (excluding obstetrics or psychiatric admissions) in 2000 were linked to one or more AEs. Furthermore, over one-third of those patients were deemed to have a “highly preventable” AE.

Hospital-acquired infections were among the most frequent type of AE examined within a 2007 report. In two different surveys conducted in 2005 and 2006, nurses and primary care physicians reported that patients were more likely to acquire an infection while in a health care setting, than to receive an incorrect medication or dose (Statistics Canada, 2005 and The Commonwealth Fund, 2006). Between 8,000 and 12,000 deaths of Canadians each year are attributed to healthcare-associated infections.

Significant recommendations about the prevention of hospital-acquired infections were made in response to the SARS crisis in Ontario. The SARS Commission identified a significant...
“lack of awareness within the health system of worker safety best practices and principles”. The Walker Report noted a need for “tailored infection control training for all workers across every sector of the healthcare system,” and recommended provincial infection control standards.

Employee education is a key aspect of infection control initiatives within hospitals, even though it is only one component of a comprehensive infection prevention and control system. Accreditation Canada (formerly the Canadian Council on Health Services Accreditation) requires health service organizations to provide education and staff training on handwashing/hygiene. Given the importance of infection prevention and control education training, thought and consideration should go into the design of educational programs for health care workers in the health care setting. One consideration is the learning modality to be delivered to workers. This study examines the learning preferences of nurses specifically related to infection prevention and control (IPAC). An exploratory pilot-study was implemented within the medical-surgical intensive care unit (MSICU) at the Toronto General Hospital site of the University Health Network (UHN), a three-site tertiary care teaching hospital in downtown Toronto.

**METHODS**

A questionnaire comprised of both closed and open-ended questions was administered to nursing staff on the MSICU using convenience sampling through intercept interviews, between March and June of 1999. The survey included questions on nursing demographic features (years of experience and nursing status) and learning preferences related to infection prevention and control. A selection of learning modalities were presented for nurses to choose from: seminars, reading materials/reference manual, flashcards, videos, intranet, posters, pictures, combination of text and pictures, and CD-ROM.

The nursing staff on MSICU was comprised of 140 nurses; including full-time, part-time and casual staff, in day, night, and rotating shift capacities. 72 of the 140 nurses were sampled.

Analysis of the data was carried out using SPSS 9.0. Descriptive analyses were undertaken, including frequency counts to identify preferred learning methods among nurses sampled. Cross tabulations were further employed to illustrate learning preferences among subsets of nurses sampled.

**RESULTS**

**Demographic analyses**

Figure 1 illustrates the distribution of the nurses’ years of experience. The mean length of experience among nurses sampled was 11.4 years (standard deviation of 4.83); ranging from one year of experience to 25 years.

**Employment status of nurses**

44 of 72 of nurses were full-time (day, night or rotating); 26 of the remainder were part-time (day, night or rotating) and the rest (2 of 72) were casual staff (day, night or rotating).

Figure 2 demonstrates that the proportion of full-time in comparison to part-time or casual nurse status was fairly consistent across all ranges of years of experience.

**Preferred learning modality of nurses**

Figure 3 illustrates that seminars (38 of 72 nurses) were the most commonly cited modality of nurses’ infection control learning preferences, followed by reading materials (11 of 72) and videos (9 of 72).
Smarter Cleaning.

RUBBERMAID PULSE™
FLOOR CLEANING SYSTEM

- High-capacity reservoir holds enough solution to clean up to 850 sq ft of floor space.
- Refill and clean up to 10,000 sq ft with the optional Rubbermaid Pulse™ Caddy.
- Pulse™ Caddy utilizes Clean-Connect technology to reduce exposure to chemicals.

Press the ergonomic trigger handle to deliver three streams of cleaning solution (non-atomizing for greener cleaning).

Clean floors faster and more easily: Rubbermaid Pulse™ combines industry-best microfibre and the time-saving portability of an on-board cleaning reservoir.

Learn more about Rubbermaid Pulse™ at www.rcpworksmarter.com or call 1-800-998-7004.

Work Smarter.
Four nurses cited “other” preferred modalities; three of which specified the use of a communications book. Communication books serve as a paper-based journal for nurses to communicate to each other about issues of importance on the nursing unit (e.g. patient care, hospital/corporate directives etc.).

The one “other” respondent specified a “multi-media approach” as a preferred learning modality.

**Nurse preference for infection control seminar frequency**

Figure 4 illustrates that the majority (56 of 72) of nurses indicated a preference to attend infection control seminars annually (once per year).

Ten respondents indicate a range of responses from twice a year to once every five years. The remaining six respondents indicated “other” preferences: never (n=1); once in a lifetime (n=2); the remaining three respondents did not indicate a frequency preference.

**Nurse preference for a paper-based infection control learning modality**

Of the three paper-based learning modality types offered as choices in the survey, portable flash card (22 of 72), package with text and pictures (18 of 72) and a reference manual (17 of 72) were the most common types identified by the nurses surveyed (Figure 5). Of the three nurses that cited “other” paper-based options: two emphasized the use of a communications book. The one “other” respondent specified a “portable flash card on the door”.

**Learning preferences by years of experience**

It was observed that nurses from all categories of experience (0-5 years, >5-10 years, >10-15 years and > 15 years) most commonly cited a preference for seminars as a learning modality: 3 of 6, 20 of 30, 9 of 24 and 6 of 12, respectively (Figure 6). Reading materials and videos were the other most commonly cited modalities among all experience categories. In Figure 3, of all 72 respondents, five indicated a preference for posters. These five are comprised of nurses within the >10-15 years of experience category.

**Preferred frequency of infection control seminars**

It was observed that the majority of nurses in each category of experience preferred an annual frequency of infection control seminars: 4 of 6 for the 0-5 years experience category; 22 of 30 for >5-10 years experience category; 20 of 24 for >10-15 years experience category, and 10 of 12 for nurses with greater than 15 years experience (Figure 7).

**Preference of paper-based learning formats of nurses by years of experience**

It was observed that portable flash cards, package with text and pictures and a reference manual were the top three preferences for paper-based infection control learning modalities among nurses from all experience categories. For the 0-5 years of experience and over 15 years of experience category of nurses, reference manuals were the most cited: three of six and five of 12, respectively. Portable flash cards as a learning modality received the highest number of counts for the >5-10 years experience and >10-15 years experience categories: 11 of 30 and 8 of 24, respectively (Figure 8).
DISCUSSION

Given a range of options of educational formats for infection prevention and control (IPAC) in 1999, our pilot study found that the majority of the nurses sampled indicated a preference for face-to-face infection prevention and control education. This may align with the theories and principles of andragogy. Further, when given a choice, the nurses sampled indicated a frequency for such engagements on an annual basis. This was observed in every category of years of experience. Given the challenges that exist for nurses participating in continuing education, including scheduling problems9 this is an important finding and should help to inform the development of IPAC training programs for HCW (The Canadian Nurses Association, 1997)10. Despite today’s advances in technology, which can assist to increase access to education on patient floors for HCW, these findings of 1999 may still hold true.

The learning preferences of paper-based learning formats was further explored in our study, and it was found that, among those sampled, portable flash cards, packages with text and pictures, and reference manuals were the most preferred options. These preferred choices might suggest a need to have easily accessible infection control reference materials on patient care floors. The desire for portable flash cards may suggest a need for a mobile reference source for nurses on the floor. With today’s move toward enhanced technology, access to infection prevention and control materials on PDAs may be a consideration. These learning formats could be explored in concert with infection control seminars.

Furthermore, the authors have observed, even though the data findings date to 1999, that the learning preferences of HCW have not changed substantively, despite the introduction of information technology on patient care floors. Although technology has started to change the context of infection prevention and control education for nurses, web-based education among nurses remains under-utilized11. Insufficient computer proficiency has been shown to prohibit nurses from participating in internet-based courses11. Technology is not the panacea for infection prevention and control education, despite its many benefits. There are many emerging learning modalities being offered to health care workers that focus on patient safety today. One example of these new modalities is the Infection Prevention and Control Core Competency Education program for health care providers in Ontario12. The first three modules for acute-care professionals were launched in June 2007 via CD-ROM (computer based). These modules are not mandatory to complete, but could fulfill Accreditation Canada’s (or other requirements) for providing education and staff training on handwashing/hygiene. Furthermore, the Ontario Ministry of Health and Long-Term Care13 also launched a self-directed online handwashing resource (Just Clean your Hands). Assessing the effectiveness and nurse uptake/reception of such modalities will be key to monitor.

It is interesting to note that the most commonly cited preferred learning modalities were the same for each category of years of nursing

![Figure 5: Nurse Preference of Paper Based Infection Control Learning Formats](image1)

![Figure 6: Learning Preferences of Nurses by Years of Experience](image2)
experience. The authors assumed that younger nurses would have indicated a preference for more technology-oriented learning modalities compared to those with more years of experience. This was not observed. This observation may help to inform infection control practitioners when developing educational programs. However, the sample size for this subgroup (up to five years of experience) was very small (n=6).

Despite the relevance and importance of IPAC training, it must exist alongside organizational support\textsuperscript{14}. It has been noted that individual HCW factors (knowledge, attitudes) are less important to focus upon within health care training than communicating clear organizational policies, procedures and expectations and support for infection control/safety\textsuperscript{14}. Furthermore, an improvement in infection control practices and a corresponding reduction in nosocomial infection rates can be attributed to modifying the organizational culture (e.g. clear management buy-in, encouragement among colleagues and formal safety training)\textsuperscript{15}.

**SUMMARY**

The post-SARS health care system landscape has created significant impetus for health care organizations to strengthen their commitment to infection control and safety. This organizational commitment should be reinforced through future training opportunities for HCWs. Although the nurses surveyed in this study indicated a preference for attending infection control seminars annually, it is important to assess the effectiveness of specific needs/preferences of HCWs before designing educational interventions. The practicality of nurse participation in various educational initiatives also must be considered within the context of their busy work environments\textsuperscript{16}.

With recent developments in Ontario (e.g., commitment to address the health care human resource needs and the introduction of technology to the patient floors), strengthened focus on patient safety will assist in enhancing the capacity of infection control training amongst health care providers. While findings may not be generalizable, this study does provide valuable insight on this understudied area, and does encourage future investigation given the new norm in infection prevention and control. Acute care settings are advised to accurately assess the IPAC learning needs of nurses, the effectiveness of these preferred learning modalities in improving IPAC practices, and to explore differences relative to different nursing characteristics (e.g. years of experience).

**ACKNOWLEDGEMENTS**

The support of Maude Foss (Clinical Director, University Health Network; former MSICU Nurse Manager) and staff of the Medical-Surgical Intensive Care Unit (MSICU) of Toronto General Hospital, University Health Network was instrumental to the authors surveying nurses within the MSICU during work shifts.

Dr. John Conly (Professor and Head of the Department of Medicine at the University of Calgary and the Calgary Health Region) provided
oversight of the research in his former role as Director of the Infection Prevention and Control Unit of the University Health Network.

Yasuko Enosawa (Legislative Archivist, Legislative Assembly of Ontario) conducted literature searches.

Ecolab Ltd. provided initial funding to support the research activities.

Dr. Bryn Greer-Wootten (Associate Director – Institute for Social Research and Professor Emeritus in Environmental Studies and Geography, York University) provided consultative support with respect to data analysis and interpretation.

REFERENCES


NEW!

The Improved

Flexi-Seal™

FMS

Dramatically Advancing Fecal Incontinence Management

Concerned about C. difficile?

Use Flexi-Seal® FMS to manage and contain infectious diarrhea

- A simple closed system
- All disposable, single patient use
- Designed to minimize the exposure of infectious waste materials

For more information, call our Customer Relations Center (Registered Nurses on staff) at 1 800 465-6302, Monday through Friday, 8:00 AM to 7:00 PM (EST), or visit our website at www.convatec.ca

Flexi-Seal is a registered trademark of ConvaTec Inc. Realize the possibilities is a trademark of ConvaTec Inc. ©2008 ConvaTec Inc.
An annual poster contest is sponsored by Ecolab and supported by a chapter of CHICA-Canada to give infection prevention and control professionals (ICPs) an opportunity to put their creative talents to work in developing a poster which visualizes the Infection Control Week theme.

YOU ARE INVITED to design a poster that will be used for Infection Control Week 2009 using the following theme:

THE POWER OF ONE!
Your Role in Infection Control

Prize: Waived registration to 2009 CHICA-Canada Conference plus $500

REMINDER: Posters should have meaning for patients and visitors as well as all levels of staff in both acute and community settings. The poster should be simple and uncluttered, with strong visual attraction and few if any additional words.

Judging will be on overall content. Artistic talent is helpful but not necessary. The winning entry will be submitted to a graphic designer for final production. Your entry will become the property of CHICA-Canada.

Include your name, address and telephone number on the back of your entry.

DEADLINE: January 31, 2009
Where Will You Put Your CaviWipes™ Flat Pack?

New adhesive-backed CaviWipes Flat Pack makes surface disinfection more convenient.*

- **Unique Design.** Resealable soft pack offers infection prevention at your finger tips.
- **Fast Action.** Kills TB, MRSA, HIV-1 and HCV in 3 minutes.
- **More Value.** A cleaner and disinfectant in one.
- **Fully Saturated Wipes.** 7-layer design that drenches surfaces with the power of CaviCide®
- **Space Saver.** Minimize storage space and unclutter counter space.
- **Non-abrasive.** For use on hard, non-porous surfaces.
- **Durable.** Non-woven towelettes that won’t bunch up during use.

Visit metrex.com or call 800.841.1428 for more information!
CHICA-Canada *Clostridium difficile* Research Fund

**Application:**

- **Project Title** ___________________________________________ **Date of Application** ________________
- **Name of Principal Investigator** ___________________________ **CHICA Member #** ________________
- **Phone Number** ___________________________ **Email Address** ___________________________
- **Name of Co-Investigator(s)** ___________________________________________
- **Name of Employer or Institution where research will take place** ___________________________________________
- **Mailing Address** ___________________________________________

*Please check appropriate box.*

- Ethics Approval Required:  □ Animal  □ Human  □ Not Applicable

I, the undersigned, certify that the statements in this proposal are true and complete to the best of my knowledge and accept, if a grant is awarded, the obligation to comply with the terms and conditions in effect at the time of the award.

**Signature** ___________________________________________ **Date** ________________

Please contact the Director of Programs and Projects (Karen Clinker at 1-807-223-4408 or clinkerK@tbh.net) with any questions.

---

**Application Guidelines**

1. This form is to be completed by individuals requesting support from the CHICA-Canada *Clostridium difficile* Research Fund.

2. Research grants are for studies designed to provide new knowledge that is readily applied to the practice of infection prevention and control in the prevention of *Clostridium difficile*. Basic biological studies on the organism and its toxins are out of the scope of this project. Clinical trials on the treatment of *Clostridium difficile* are also excluded. Applications will be accepted from publicly funded hospitals, universities, and community colleges.

3. Use of the CHICA-Canada *Clostridium difficile* Research Fund will be restricted to members of CHICA-Canada in good standing for membership year 2008.

4. A maximum of $50,000 CDN is available for research awards. Distribution of those funds will be based on the number of successful applicants and the merit of the proposals received.

5. Funds are granted for research studies to be completed within two (2) years. A progress report will be required to be submitted to the director of programs and projects at the end of the first year.

---

*The applications deadline is November 1, 2008*
Background and Significance:
Describe the current state of knowledge and significance of the topic. State concisely the importance and relevance of the research described in this application by relating the specific aims and objectives.

Objectives:
List the broad, long-term objectives of this work and the specific aims of this project. Be clear in the specific aims and state what the specific research proposed in this application is intended to accomplish.

Research Design and Methods:
Describe the research design and procedures to be used to accomplish the specific aims of the project. Include study design, target population and sample, instruments and data collection tools, procedures for collecting and managing data and data analysis and interpretation.

Timeline:
Present and outline of the sequence of planned research tasks along with an estimated duration for each task. Give proposed start date and completion date for the project.

Budget:
Provide a realistic budget, including cost estimates for supplies, services and other direct costs. Describe the rationale for why funding support is needed from this source. Mention any constraints in obtaining this support from other sources. If the project will be partially funded by another grant or by the institution, this should be specified.

References:
All references listed should be sited in the body of the research plan.

RÉSUMÉS:
RÉSUMÉS of the principal and co-investigators should be included. Maximum two (2) pages for each person.

6. A letter of support from the agency where the research will take place should accompany the proposal.
7. A notice of approval from a research ethics board and/or animal care committee should accompany the proposal, if applicable. If the notice of approval is not available at the time of submission, the approval must be submitted to the CHICA-Canada board before any funding is released.
8. The applications deadline is November 1, 2008 (must arrive by midnight on November 1). Submit completed applications to CHICA-Canada Clostridium difficile Research Fund, c/o CHICA-Canada, PO Box 46125, RPO Westdale, Winnipeg MB R3R 3S3, or by courier to: 67 Bergman Crescent, Winnipeg MB R3R 1Y9. Please submit three (3) paper copies and an electronic version to be forwarded to chicacanada@mts.net.
9. The director of programs and projects will appoint a committee to review all applications. The principal investigator (or co-investigator) will be given two weeks to respond to questions on the grant submission from the review committee. Responses to questions may be forwarded by electronic or paper mail. A final decision on funding a project will be made by the CHICA-Canada board. Successful applicants will be notified through a letter from the director of programs and projects by December 15, 2008.

As per the decision of the board, a part or none of the funds might be distributed.
10. Should the lead investigator or co-investigator of a project be a current CHICA-Canada board member, that member will declare their conflict of interest on the application form and will not participate in any evaluation, discussion or decision-making regarding the allocation of research grants.
11. Successful applicants are required to submit a report to the CHICA board on completion of the project and to submit an abstract on the results to the CHICA-Canada 2009 national conference. It is an expectation that the results will be published in a peer review journal, such as the Canadian Journal of Infection Control.
12. Applicants must prepare a written proposal that includes the following sections. Proposals should be a maximum of 10 pages (typed and double spaced, using a minimum 12 point font), excluding references and résumés and appendices.
13. In the event that funding is awarded, progress and final reports should be sent to:
Karen Clinker, Chair
CHICA-Canada Programs & Projects Committee
PO Box 46125 RPO Westdale
Winnipeg MB R3R 3S3
By courier to: 67 Bergman Crescent
Winnipeg MB R3R 1Y9
Email: chicacanada@mts.net

6. A letter of support from the agency where the research will take place should accompany the proposal.
7. A notice of approval from a research ethics board and/or animal care committee should accompany the proposal, if applicable. If the notice of approval is not available at the time of submission, the approval must be submitted to the CHICA-Canada board before any funding is released.
8. The applications deadline is November 1, 2008 (must arrive by midnight on November 1). Submit completed applications to CHICA-Canada Clostridium difficile Research Fund, c/o CHICA-Canada, PO Box 46125, RPO Westdale, Winnipeg MB R3R 3S3, or by courier to: 67 Bergman Crescent, Winnipeg MB R3R 1Y9. Please submit three (3) paper copies and an electronic version to be forwarded to chicacanada@mts.net.
9. The director of programs and projects will appoint a committee to review all applications. The principal investigator (or co-investigator) will be given two weeks to respond to questions on the grant submission from the review committee. Responses to questions may be forwarded by electronic or paper mail. A final decision on funding a project will be made by the CHICA-Canada board. Successful applicants will be notified through a letter from the director of programs and projects by December 15, 2008.

As per the decision of the board, a part or none of the funds might be distributed.
10. Should the lead investigator or co-investigator of a project be a current CHICA-Canada board member, that member will declare their conflict of interest on the application form and will not participate in any evaluation, discussion or decision-making regarding the allocation of research grants.
11. Successful applicants are required to submit a report to the CHICA board on completion of the project and to submit an abstract on the results to the CHICA-Canada 2009 national conference. It is an expectation that the results will be published in a peer review journal, such as the Canadian Journal of Infection Control.
12. Applicants must prepare a written proposal that includes the following sections. Proposals should be a maximum of 10 pages (typed and double spaced, using a minimum 12 point font), excluding references and résumés and appendices.
13. In the event that funding is awarded, progress and final reports should be sent to:
Karen Clinker, Chair
CHICA-Canada Programs & Projects Committee
PO Box 46125 RPO Westdale
Winnipeg MB R3R 3S3
By courier to: 67 Bergman Crescent
Winnipeg MB R3R 1Y9
Email: chicacanada@mts.net
Did you know ... 

In 2002, the International Infection Control Council (I2C2) published the *Infection Control Toolkit: Strategies for Pandemics and Disasters*. With the advent of SARS and the H5N1 influenza virus, as well as other natural disasters and disease outbreaks since 2002, the I2C2 recognized the need to update and revise the previous toolkit.

The content has been updated and reformatted into the newest version *Infection Control Toolkit for Emergencies and Disasters*. The purpose of the toolkit is to assist IPCPs in the preparation and implementation of plans for emergencies and disasters.

The revised toolkit is now available at $120.00 CDN (Member rate) plus shipping & handling and GST.

---

**Bio-Safe Skin Shield®** because health is in your hands.

- **Bio-Safe Skin Shield** increases hand washing compliance and prevents contamination from MRSA & VRE.
- **Bio-Safe Skin Shield** protects against damage from frequent use of alcohol sanitizers, hand washing and glove use. This patented lotion provides an 8 hour barrier effect that prevents occupational dermatitis as it relates to the health and food-service industries. The result keeps staff's hands from getting red, chapped and sore which therefore helps increase handwashing compliance.
- Clinical trials at a Canadian Acute Care Hospital showed that patients whose nurses used the control lotion were 9.0 times more likely to develop MRSA, versus the ward where nurses wore Bio-Safe Skin Shield lotion.
- Bio-Safe Skin Shield® is a patented polymer lotion that is registered with a DIN and has CFIA approval for food handlers.

For pennies per day join the war against the spread of MRSA/VRE.

---

Watch for on-line abstract submissions for the 2009 National Education Conference; the link will be launched November 1, 2008. www.chica.org
1983 cohort honoured

Members of the cohort who took the first certification examination in 1983 honored at CBIC Reception at APIC National Conference in June.
When it comes to patient well being, Hollister brings more innovation to healthcare. The Zassi® Bowel Management System diverts and contains potentially infectious stool. It is the only indwelling rectal catheter that provides access for rectally administered medications.

**C. the difference**

See how the Zassi® Bowel Management System can help your patients. Call 1.800.263.7400 or email bowel.management@hollister.com and discover why ... There's more to Hollister than ever before.

**Caution:** This device is intended to be used by or on the order of a physician.

Prior to use of the Zassi® Bowel Management System, be sure to read (a) the entire Zassi® Bowel Management System Instructions for Use package insert supplied with the product for device intended Use, Description, Contra-Indications, Warnings, Precautions, Adverse Events, and Instructions for Use and (b) all other package inserts and other inserts supplied with the product and accessories. Date of Issuance: October, 2007

Hollister and logo and “Attention to Detail. Attention to Life.” are trademarks of Hollister Incorporated.

Zassi is a trademark of Zassi Medical Ventures, Inc. licensed by Hollister Incorporated.

Covered under one or more of the following patents: US Patent 5,902,716, 7,147,767 and Australia Patent 2002341856 and other patents pending.

©2007 Hollister Incorporated

www.hollister.com
2009 NATIONAL EDUCATION CONFERENCE

CALL FOR ABSTRACTS
Online abstracts submission will be available as of November 1, 2008 at www.chica.org.

Deadline for Submission: Friday, February 27, 2009
ABSTRACTS MUST BE SUBMITTED ONLINE ONLY. Link from www.chica.org

Abstracts for presentation at the 2009 National Education Conference will be accepted until 5:00 pm Pacific Standard Time, February 27, 2009. The Abstract Committee reserves the right to select papers for presentation on the basis of relevance and interest, and to choose the types of presentation. Oral paper presenters will be provided with a 15-minute session (10-minute presentation; 5-minutes Q&A). Poster session presenters will be provided with a 45-minute opportunity to answer questions while at their poster. Presenters will be notified of acceptance by the end of March 2009 and will be advised of the date and time of their presentation.

Abstract Preparation and Guidelines for Acceptance

A. Content
1. Abstracts must be submitted online using the template provided. The template will be provided after the author has registered online. Make sure all sections are completed.
2. Abstracts should be based on results that have not or will not be published or presented before the meeting date.
3. The potential significance of the observations, as well as the scientific and/or educational quality of the work will influence which abstracts are accepted. Where possible, the author(s) should emphasize the features of the project that are new or different.
4. Abstracts must present scientific research and not direct promotion of a specific product(s).
5. All concepts and abbreviations must be defined at first use in the body of the abstract.
6. Any corporate assistance must be acknowledged.
7. Any sources of funding must be acknowledged.
8. Text must not exceed 250 words or must fit within the online template with a minimum of a 10-pt font.

B. Format
Abstracts should be submitted in one of the following formats:

Format 1: This format is intended for abstracts involving the presentation of scientific research findings, such as randomized clinical trials, case-control, observational or descriptive studies, or outbreak investigations where appropriate comparisons or analyses of data have been performed.

Note: The abstract should disclose primary findings and not include statements such as “experiment in progress” or “results will be discussed.”

Abstract Title: (Initial caps and bold)
Authors: The presenter must be denoted with an asterisk, e.g. J. Cabot*, H. Gilbert, St. John’s Hospital, St. John’s.

Background/Objectives: Outline study objectives, the hypothesis to be tested, or description of the problem.

Methods: Report methods used or approach taken.

Results: Indicate essential results obtained in summary form with appropriate statistical analysis (p value, confidence intervals, odds ratio, etc.)

Conclusions: Provide a summary of findings as supported by results with implications and conclusions.

Format 2: The format is intended for abstracts involving the description of educational or performance improvement programs, observations, or other infection prevention activities, including descriptions of facility or community based programs or interventions, discussions or infection prevention policy, and descriptions of a particular prevention model or method.

Abstract Title: (Initial caps and bold)
Authors: The presenter must be denoted with an asterisk, e.g. G. Marconi*, Mount Pearl Community Centre, St. John’s.

Issue: Identify the specific problems or needs addressed. Provide brief introduction of the proposed topic. Include important background and current information on issues.

Project: Description of the intervention/program.

Results: Specific results in summary form.

Lessons Learned: Summary of the lessons learned and implications.
C. Setting (choose one)
- Acute Care
- Long Term Care/Continuing Care
- Community/Public Health
- Occupational Health

D. Subject Categories (select only one)
The author(s) should select the one subject category that best categorizes the submissions. This will assist conference planners in organizing the program.
- Antimicrobial Resistance
- Cleaning, Disinfection, Sterilization
- Education
- Emerging Pathogens
- Outbreak Investigation
- Pediatrics
- Practice Standards/Guidelines
- Program Evaluation
- Quality/Process Improvement
- Site Specific Infections
- Surveillance
- Other

E. Preferred Method of Presentation if Abstract Selected (choose one only)
- Poster
- Oral presentation
- No preference

F. Guidelines for Abstract Selection
Abstracts not meeting the stipulations outlined under both A (Content) and B (Format) above will not be considered for acceptance.

Submission of Abstracts
1. Abstracts must be submitted online using the template provided. Make sure all sections are completed.

Link to Abstracts Submission page via www.chica.org
2. Abstracts must be submitted by 5:00 pm Pacific Standard Time, Friday, February 27, 2009.
3. Abstracts will be reproduced and submitted for inclusion in the preconference issue of the Canadian Journal of Infection Control. Abstracts will be posted to the 2009 Conference page of www.chica.org prior to the conference. Presenters must be registered at the conference but do not have to register prior to submitting abstract.
4. Instruction for online submissions will be available at the abstracts site. Information to be included is:
   - Full name, professional mailing address, telephone and email address of the author who will present the paper.
   - Preference: Oral Presentation, Poster Presentation, or No Preference
   - Indication if the presenter is a First Time Presenter.
   - Indication if the author(s) is/are interested in authoring an article for publication in the Canadian Journal of Infection Control.

REGISTRATION BROCHURE
Watch for the Registration brochure to be posted in December 2008 and mailed in January 2009.

2009 SCIENTIFIC PROGRAM COMMITTEE
Conference Chair
Joanne Laalo, RN, BScN, CIC
Central South Infection Control Network, Dundas, Ontario

Scientific Program Chair
Donna Moralejo, PhD
Memorial University School of Nursing, St. John’s, Newfoundland Labrador

2009 Scientific Program Co-chair
Jim Gauthier, MLT, CIC
Providence Care, Kingston, Ontario

Scientific Program Committee
Molly Blake, BN, MNS, GCN(C), CIC
Health Sciences Centre, Winnipeg, Manitoba

Lee Hanna, RN, CIC
Good Samaritan Society, Edmonton, Alberta

Penny Ralph, RN, CIC
Central Newfoundland Regional Health Care, Grand Falls-Windsor, Newfoundland Labrador

Diane Roscoe, MD, FRCPC
Vancouver General Hospital/Vancouver Coastal Health, Vancouver, British Columbia

Merlee Steele-Rodway, RN
City Hospitals – Eastern Health, St. John’s, Newfoundland Labrador

Marion Yetman, RN, BN, MN, CIC
Department of Health and Community Services
Government of Newfoundland Labrador, St. John’s, Newfoundland Labrador

CONFERENCE HOTEL
Delta St. John’s
120 New Gower Street
St. John’s, Newfoundland Labrador A1C 6K4

2009 Rates to be confirmed (January 2009)
Single/Double Occupancy: $162
Additional Person sharing a room: $20 per night. No charge for up to two children 18 years old and sharing their parents’ accommodation. The maximum legal number of occupants is four (4).

Plus Marketing Tourism Levy of 3% per room per night and Provincial Sales Tax of 13%.

2009 EDUCATION CONFERENCE EXHIBIT AND SPONSORSHIP OPPORTUNITIES

An Industry Showcase will be held to give attendees the opportunity for further knowledge and education through viewing and discussion of products and services in the field of infection prevention and control. Exhibit information packages will be available in the autumn of 2008. Booth rentals are $1,800 each (6’x10’ booth) plus GST. Set up: Monday, May 11; tear down Wednesday, May 13.

Guidelines for sponsorship of the conference are available from CHICA-Canada. Sponsors of the conference benefit from additional promotion of their company as well as direct benefits through discounted booth fees, complimentary registration, and the opportunity to hold a mini symposium with specific product information. For more information, contact CHICA-Canada Conference Planner.

RALLY IN THE ALLEY

Wednesday, May 13, 2009

You will be accompanied from the Delta St. John’s to famous George Street where you will: Experience the fun and camaraderie of St. John’s. Enjoy a lobster dinner,* learn local step dancing, learn some local songs and be welcomed into the Order of Screechers! It is a time to be remembered for years to come.

Fee $100.00 per person (includes HST) Fees include: Lobster Dinner, entrance to pubs, one complimentary beverage at each location, a shot of Screech, musicians to lead each group, and entertainment at each venue.

*Chicken or vegetarian alternates available on request (See Registration Form January 2009). (Lobster is traditionally served cold – banquet style).

KEYNOTE SPEAKER, Tuesday, May 12

Linda Duxbury

You, Me and Them - Understanding Generational Differences In The Workplace

Linda Duxbury, MASc (Chem Eng), PhD is a professor at the Sprott School of Business, Carleton University. Dr. Duxbury teaches masters and PhD courses in managing change as well as the masters course in organizational behaviour. In the past decade she has studied issues surrounding balancing work and family, the organizational and individual impacts of communication technology, and generational differences in work values. It is the latter area that will be the focus of the 2009 keynote speech.

Dr. Duxbury held the Imperial Life Chair in Women and Management from 1992 to 1996 and was director of Carleton Centre for Research on Education on Women and Work from 1996 to 1999. Acknowledgement of her teaching and speaking excellence has been bestowed upon her many times, including the Canadian Workplace Wellness Pioneer Award (2002) for her “pioneering efforts, creativity, innovation and leadership” in the field of organizational health; the Carleton University Students’ Association 2002-2003 Teaching Excellence Award for her “ability to convey enthusiasm, responsibility in teaching practices, approachability and communication skills”; and the Toastmasters International Communication and Leadership Award by District 61 (2007) for her “outstanding personal contribution to our community as a powerful communicator and a dedicated leader.”

CLOSING SPEAKER, Thursday, May 14

Michael Borg, MD, M.Sc. (Lond), DLSHTM, MMCPath

President, International Federation of Infection Control

Overcoming Limited IP&C Resources

How IP&C is established and sustained when resources are limited – a global view.

Michael A. Borg was appointed microbiologist with the Health Department of Malta in 1991 and subsequently consultant in hospital infection control. He chairs both the Infection Control Committee of St. Luke’s Hospital, a 900-bed tertiary care facility, and the Antibiotic Team at the same institution. He is also strongly involved in infection control and antibiotic initiatives on a national level where he chairs the Malta National Antimicrobial Committee.

He has been invited to participate as an expert in several European meetings including the Intergovernmental workshop on the Prevention of Hospital-acquired Infection in Member States of the Council of Europe and is a permanent member of the EU working group on the prudent use of antimicrobial agents in human medicine.

A lecturer with the University of Malta, his research concerns focus predominantly on the prevention and control of healthcare associated infections and appropriate antibiotic use, about which he has published in both local and international journals. He is particularly interested on the epidemiology of antimicrobial resistance and its drivers (infection control and antibiotic consumption) in developing countries. To this end, he has been the driving force and project leader for ARMed (www.slh.gov.mt), an EU-funded study evaluating these issues in the southern and eastern Mediterranean region.
Hand Hygiene Solutions for Healthcare Personnel

HYGENIPAK®

An effective hand hygiene program is the best way to help prevent infections and protect healthcare workers, patients and residents. Pleasant and user-friendly, Hygenipak skin cleansers control the spread of infectious diseases by increasing hand washing compliance.

Hygenipak cleansers are ideal for all healthcare personnel working in areas of care. Available in a variety of lotions, gels and foams, including anti-microbial, there’s a cost effective cleanser for every need and skin type.

Our focus on innovation includes patented dispensing systems, computer generated designs and new packaging that is environmentally friendly and easy to use.

For more information on hand hygiene solutions, call Deb Canada today.

deb
Deb Canada
1-888-DEB-SOAP
www.debcanada.com
New CHICA-Canada Industry Membership

A new structure for an Industry Corporate Membership has been established. This structure replaces the current CHICA-Canada Patron Membership.

Industry membership in CHICA-Canada is intended to serve the following purposes:

1. To promote education, research and collaboration through continuous professional development and research in infection prevention and control and related fields.
2. To increase all CHICA-Canada members’ contribution and participation in their respective chapters and promote interactions among members at the annual conference.
3. To follow the rules concerning maintenance of certification by professional colleges and societies (e.g. Royal College of Physicians and Surgeons of Canada, Canadian Nursing Association, etc.).
4. To build a long lasting and mutually beneficial partnership between supporting industry members and CHICA-Canada.

Membership categories and benefits

CHICA-Canada has established the four categories of industry membership with associated benefits. Entry to Industry Membership is a minimum Bronze level. All industry memberships are for one calendar year. Renewal of an industry membership must be made by March 31 for the following calendar year. The level of membership will include all membership fees and donations made to CHICA-Canada for that calendar year. Donations do not include those made to the chapters but this continues to be an important source of networking and promotion for industry as well as support for CHICA-Canada chapters and its members.

<table>
<thead>
<tr>
<th>Benefits</th>
<th>Platinum</th>
<th>Gold</th>
<th>Silver</th>
<th>Bronze (Entry Level)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complimentary Chapter Membership(s) for designated representative(s)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complimentary/discount exhibit booths, maximum 2 representatives per booth;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discount on rental of exhibit booths beyond complimentary limit</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choice of exhibit location. Final allocation is at the discretion of the conference planner after discussion with the Industry Member.</td>
<td>1st choice</td>
<td>2nd choice</td>
<td>3rd choice</td>
<td>4th choice</td>
</tr>
<tr>
<td>Industry members will be acknowledged, with their approval, as sponsors of the following speaking events during the conference in the printed and web published programs and by signage at the meeting (see more details below). Additional sponsorship may be discussed with the conference planner. Final sponsorship allocation is dependent on the content of the scientific program. Should the described sponsorship benefits not be available, the conference planner will make every attempt to provide satisfactory placement of sponsorship acknowledgement.</td>
<td>Keynote speaker, and one other plenary session on day one of conference</td>
<td>One plenary session on day two of conference, and one of the oral concurrent sessions</td>
<td>One of the oral concurrent sessions</td>
<td></td>
</tr>
<tr>
<td>Opportunity to host an educational symposium program.</td>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opportunity to conduct industry sponsored meeting social activities</td>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complimentary conference registration for representatives</td>
<td>All representatives</td>
<td>All representatives</td>
<td>2 representatives</td>
<td>2 representatives</td>
</tr>
<tr>
<td>Number of closing special event tickets</td>
<td>5</td>
<td>4</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Electronic mailing list of current CHICA-Canada members for mailings during the year of membership. The database will include the member mailing address only.</td>
<td>4 mailings</td>
<td>3 mailings</td>
<td>2 mailings</td>
<td>1 mailing</td>
</tr>
<tr>
<td>Benefits</td>
<td>Platinum</td>
<td>Gold</td>
<td>Silver</td>
<td>Bronze (Entry Level)</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>----------</td>
<td>-------</td>
<td>--------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Electronic mailing list of attendees pre and post conference for mailing during the year of membership. The database will include the member mailing address and email address.</td>
<td>4 mailings</td>
<td>3 mailings</td>
<td>2 mailings</td>
<td>1 mailing</td>
</tr>
<tr>
<td>Complimentary CHICA-Canada Member and Source Guides (number of copies as indicated)</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Web link on CHICA-Canada Industry Member web page</td>
<td>Extra Large Link</td>
<td>Large Link</td>
<td>Medium Link</td>
<td>Small Link</td>
</tr>
<tr>
<td>Discount on advertising in the Industry Update page of the website.</td>
<td>50%</td>
<td>25%</td>
<td>10%</td>
<td>10%</td>
</tr>
<tr>
<td>Discount on advertising space in 4 issues (one year) of <em>Canadian Journal of Infection Control</em> (CJIC)</td>
<td>15%</td>
<td>15%</td>
<td>10%</td>
<td>10%</td>
</tr>
<tr>
<td>Discount on advertising space in that year’s CHICA-Canada directory</td>
<td>15%</td>
<td>15%</td>
<td>10%</td>
<td>10%</td>
</tr>
<tr>
<td>One associate membership in CHICA-Canada (non-voting)</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>A subscription to the <em>Canadian Journal of Infection Control</em></td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Acknowledgement in the <em>Canadian Journal of Infection Control</em> of your membership and its level</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Acknowledgement of Industry Memberships by signage and verbally at the opening ceremonies of the conference</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>On-site booth signage acknowledging your Industry Membership Level</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Acknowledgement of Industry Membership Level on correspondence related to meeting and meeting materials</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
</tbody>
</table>

**Industry relations committee**

The Community and Hospital Infection Control Association – Canada (CHICA-Canada) is pleased to announce the launch of its Industry Relations Committee.

The Industry Relations Committee (IRC) will work closely with the board and administration of CHICA-Canada in efforts of mutual benefit that will ultimately advance the practice of infection prevention and control. The IRC is comprised of:

- CHICA-Canada Physician Director (Chair)
- CHICA-Canada Secretary/Membership Director
- CHICA-Canada Executive Administrator/Conference Planner (ex officio)
- 10 Industry members of CHICA-Canada

At the official launch of the IRC on June 3, 2008, the following industry members of CHICA-Canada were elected to the committee:

<table>
<thead>
<tr>
<th>For 3-year term expiring 2011</th>
<th>For 2-year term expiring 2010</th>
<th>For 1-year term expiring 2009</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steris Canada Inc.</td>
<td>BD Canada</td>
<td>Virox Technologies</td>
</tr>
<tr>
<td>Covidien</td>
<td>Deb Canada</td>
<td>Maxill Inc.</td>
</tr>
<tr>
<td>Ecolab Healthcare</td>
<td>LauraLine Skincare</td>
<td>3M Canada</td>
</tr>
<tr>
<td>Les enterprises Solumed</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The Industry Relations Committee will meet in person during the annual conference and via conference call throughout the year. See the new Industry Relations Committee webpage (www.chica.org).
Because you’re committed to providing quality care

Choose PURELL® 70 Instant Hand Sanitizer for effective germ kill.

New 70% Ethyl Alcohol, fragrance free formulation
From a brand you can trust.

Antiseptic Cleanser. Kills harmful bacteria or germs. Use as part of the daily cleansing routine. Place enough product in your palm to thoroughly cover your hands. Rub hands together briskly until dry.

CAUTIONS: Flammable. Keep away from fire or other heat sources. This product is intended for external use only. When using this product do not use in or near the eyes. In case of contact, rinse eyes thoroughly with water. Discontinue use and consult a doctor if irritation or redness develops. Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

GOJO, inventors of PURELL® instant Hand Sanitizer, is committed to providing well being solutions for hygiene and healthy skin.

For more information, call GOJO at 800-321-9647 or visit www.GOJO.com.

©2008. GOJO Industries, Inc. All rights reserved. *PURELL is a trademark of Johnson & Johnson and is used under license.
“Bug a Doc!”

They have a specialty – infectious disease, microbiology, epidemiology – that enhances the practice of infection prevention and control.

They should be part of CHICA-Canada.

If you have a ‘Doc’ in your department who is not yet a CHICA-Canada member, encourage your ‘Doc’ to join CHICA. Their immediate benefit is an expansion of their professional resources and networking opportunities. Go to our website and see the many benefits available to membership so you will have the information on hand when the discussion comes up!

Send us the name of your ‘Doc’ when he or she joins CHICA. You and your Doc could each win a free 2010 membership (value $125).

“Bug a Doc” contest closes March 1, 2009.

CHICA-Canada Member ________________________________
Address _______________________________________
_________________________________________________
Telephone _________________________________________
Email _____________________________________________

New ‘Doc’ Member ________________________________
Address _________________________________________
_________________________________________________
Telephone _________________________________________
Email _____________________________________________

Forward to CHICA-Canada, Fax 1-204-895-9595 or email chicacanada@mts.net
The Power of Collaboration!

Join your APIC colleagues and other healthcare professionals on

**June 7 -11, 2009 in Ft. Lauderdale, Florida**

**Important Dates to Remember:**

- **Call for Abstracts Open** - October 17, 2008 - December 19, 2008
- **Registration and Housing Open (Members Only)** - November 24, 2008
- **Registration and Housing Open (Open to All)** - December 1, 2008

Visit [www.apic.org](http://www.apic.org) for details and the most up-to-date information.
3M Canada
Infection Prevention Research Grant

As part of an ongoing initiative to promote innovative infection control and prevention practices in Canadian healthcare, 3M Canada has created a research grant through its Infection Prevention Platform. The research grant is targeted to individual members of the Community and Hospital Infection Control Association – Canada (CHICA–Canada) for use in research studies. The research grant will be a one-time payment offered on an annual basis.

One research grant of $6,000 to the Principal Investigator of the successful application will be presented at the 2009 CHICA–Canada National Education Conference in St. John’s, Newfoundland Labrador, May 9-14, 2009. Travel, accommodations and meals will be provided by 3M Canada Company for the successful recipient.


Applications must be sent to:
Secretary/Membership Director
CHICA-Canada, PO Box 46125 RPO Westdale
Winnipeg MB R3R 3S3

Or courier to:
Secretary/Membership Director
CHICA-Canada, 67 Bergman Crescent
Winnipeg MB R3R 1Y9

3M Innovation

Cleaning to Protect Public Health

Introducing ...
DFC Din Registered Disinfectant/Disinfectant Cleaners with natural cleaning agents and dilute concentrations of sodium hypochlorite.

DFC Detergent Free Oxidizing cleaners offer enhanced cleaning, post dilution stability and closed looped dispensing from concentrate.

These new safer to use cleaning products enhance cleaning, while oxidizing for a thorough and complete cleaning of organic soils on environmental surfaces.

DIN Registered Disinfectant/Disinfectant cleaners now available through the following local distributors:
For information please contact your local Wesclean Equipment and Cleaning Supplies, Swish Maintenance Limited, or Larose et Fills branch location or call Chemspec Canada 1.800.268.6093
One Syringe. Two Solutions.

Employee Safety: retractable needle

Patient Safety: integral write-on stripe

Introducing InviroSNAP!® with InviroSTRIPE® the only syringe that protects patients and employees.

With its integral write-on stripe, the InviroSNAP! with InviroSTRIPE Safety Syringe is the only syringe that helps protect against medication labeling errors and needlestick injuries. The revolutionary stripe technology combined with our easy-to-use retractable safety syringe provides unprecedented protection for healthcare professionals and their patients. Exclusively from Inviro Medical, the patented InviroSTRIPE is now available on our full portfolio of safety and standard luer lock syringes.

Because you have to be right, choose InviroSTRIPE.

Order a sample at 678.405.4027 or visit www.inviromedical.com and discover the latest innovation in patient and healthcare worker safety.
CHICA-Canada Infection Control Audit Toolkit

Available from CHICA-Canada through the CHICA-Canada Programs and Projects Committee, this series of infection control audit templates will assist you in your practice of infection prevention and control in a variety of health care settings. Topics include:

- Dental Audit
- Endoscopy Audit
- Haemodialysis Unit Audit
- High Level Disinfection - Outside SPD Audit
- Infection Prevention and Control Risk Assessment Guide
- Hospital-wide Infection Control and Prevention Audit and Template
- Ophthalmology O.R. Cluster Investigation and Procedure Assessment
- O.R. Audit
- Patient/Resident Service Units Audit
- Renal Unit Infection Control Audit
- Respiratory Outbreaks in Long Term Care Facilities Audit

Enhanced Teleclass Recordings on CD

Available exclusively from CHICA-Canada in partnership with Webber Training Inc. Topics include:

- Disinfecting Patient Care Equipment; Exploring CDC Hand Hygiene Guidelines; Airborne Spread of Human Pathogens; Disinfectants in Infection Control; Hands and the Spread of Human Pathogens; Current Best Practices in Hand Hygiene; Hand Sanitizers and their Effect on Viruses; Innovations in Hand Hygiene; Influenza Pandemic on the Doorstep; Controlling MRSA and VRE; Scientific Solutions to the Norovirus Problem; Strategies for Norovirus Infection Control on Cruise Ships; Relative Impact of Hand Hygiene on Healthcare-Associated Infections; Evidence Behind Control Measures for MRSA and VRE; Environmental Infection Control in Healthcare Facilities; Hand Hygiene – Different Approaches; Antiseptic Practice and Procedure; Glutaraldehyde Toxicology and Management of Risk; New WHO Hand Hygiene Guidelines; Respiratory and GI Outbreaks in LTC; Biofilms in our Environment; Infection Control in Day Care Facilities; Disease Transmission in the Home; Hands and Viral Infections; Infection Control in Long Term Care; Innovations in Hand Hygiene; Preventing MRSA and VRE; Advances in Global Infection Control; Bedside Hand Hygiene Products; C.difficile and Environmental Cleaning; Preventing Ventilator Associated Pneumonia – Applying the Science; C.difficile: Environmental Survival; The Toilet Bowl-Blues; Surface Disinfectants and Environmental Impact; The Spectre of a Flu Pandemic: Is it Inevitable?

ESBL TOOLKIT

Best Infection Control Practices for Patients with Extended Spectrum Beta Lactamase Enterobacteriaceae – An infection control toolkit developed by the International Infection Control Council (APIC, CHICA-Canada, ICNA (UK, Ireland)).

“Just Wash ‘Em “Lavez les”

A 7 minute video directed to Elementary School aged children.

Reaching today’s kids with our all-important handwashing message is a major step in preventing the spread of infection. CHICA-Canada’s very own Sudsy makes his debut in a creative, fun-to-watch handwashing video aimed at school-aged children. Great for school projects, seminars and demonstrations.

The Infection Control Toolkit: Infection Control in Emergencies and Disasters

The only disaster planning document that presents information specific to the key issues of infection control. Includes all the tools and materials necessary for surveillance, education, communication, laboratory, and management of personnel and patients are included. Handy forms, references, fact sheets, flowcharts, checklists, and samples provide the framework to interface with healthcare facilities and local public health preparedness plans. No other disaster planning document presents information specific to the key issues of infection control.

ARO VIDEO

A 15 minute educational video covering topics related to AROs (epidemiology, surveillance and control). Produced in cooperation with Wyeth, with assistance from CHICA-Canada members.
<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>QUANTITY</th>
<th>MEMBER RATE</th>
<th>NON-MEMBER RATE</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Just Wash 'Em VHS Video© – no workbook</td>
<td></td>
<td>$34.95</td>
<td>$39.95</td>
<td></td>
</tr>
<tr>
<td>Just Wash 'Em VHS Video© with workbook</td>
<td></td>
<td>44.95</td>
<td>49.95</td>
<td></td>
</tr>
<tr>
<td>Just Wash 'Em DVD© – no workbook</td>
<td></td>
<td>38.95</td>
<td>43.95</td>
<td></td>
</tr>
<tr>
<td>Just Wash 'Em DVD© With workbook</td>
<td></td>
<td>48.95</td>
<td>53.95</td>
<td></td>
</tr>
<tr>
<td><strong>10% Discount on 3 or more!</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lavez les! VHS Video© – no workbook</td>
<td></td>
<td>34.95</td>
<td>39.95</td>
<td></td>
</tr>
<tr>
<td>Lavez les! VHS Video© with workbook</td>
<td></td>
<td>44.95</td>
<td>49.95</td>
<td></td>
</tr>
<tr>
<td>Lavez les! DVD© – no workbook</td>
<td></td>
<td>38.95</td>
<td>43.95</td>
<td></td>
</tr>
<tr>
<td>Lavez les! DVD© with workbook</td>
<td></td>
<td>48.95</td>
<td>53.95</td>
<td></td>
</tr>
<tr>
<td><strong>10% Discount on 3 or more!</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARO Video© – Across the Spectrum of Care</td>
<td></td>
<td>20.00</td>
<td>25.00</td>
<td></td>
</tr>
<tr>
<td>Le MRA© – Dans tout le spectre des soins</td>
<td></td>
<td>20.00</td>
<td>25.00</td>
<td></td>
</tr>
<tr>
<td>Infection Control Audit Toolkit</td>
<td></td>
<td>120.00</td>
<td>150.00</td>
<td></td>
</tr>
<tr>
<td>Infection Control in Emergencies and Disasters Toolkit</td>
<td></td>
<td>120.00</td>
<td>150.00</td>
<td></td>
</tr>
<tr>
<td>ESBL Toolkit</td>
<td></td>
<td>120.00</td>
<td>150.00</td>
<td></td>
</tr>
<tr>
<td>Webber Training Teleclass CD (attach list of recordings to be ordered)</td>
<td></td>
<td>55.00 – no shipping &amp; handling fee</td>
<td>55.00 – no shipping &amp; handling fee</td>
<td></td>
</tr>
<tr>
<td>+ Shipping and Handling</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Orders less than $50 - $8.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Orders $51-$100 - $10.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Orders $101-$150 - $12.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Orders over $151 – 15%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No shipping and handling on Webber Teleclass CDs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>For courier shipments, add $25.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SUB-TOTAL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Shipping &amp; handling</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GST/HST</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*GST/HST – GST 5% of total amount, including shipping & handling; HST 13% of total amount including shipping & handling (payable by residents of New Brunswick, Newfoundland, Nova Scotia). No GST/HST applicable on orders from outside Canada. BN 11883 3201 RT0001.

Send order to: CHICA Canada, PO Box 46125 RPO Westdale, Winnipeg, MB R3R 3S3 • Email: chicacanada@mts.net • Fax: 1-204-895-9595

I am paying by cheque, payable to CHICA-Canada – enclosed

I am paying by credit card – VISA/MasterCard/AMEX

Credit Card Number __________________________ Expiry Date __________________________

Name of Cardholder (print) __________________________________________________________

Signature of Cardholder ____________________________________________________________

SHIP TO:

Name ____________________________________________________________

Address ____________________________________________________________

______________________________

Telephone __________________________
The VanishPoint® Advantage
Designed for Clinician and Patient Safety

- Clear, unobstructed calibrations allow for accurate dosing
- Triple beveled, lubricated needle provides patient comfort
- EASY, ONE-HANDED ACTIVATION
- Pre-removal activation prevents exposure to contaminated sharp
- NO CONTAMINATED SHARP EXPOSED
- Attached needle prevents leakage and contamination
- Activated VanishPoint® Syringes require less disposal space than other syringes and prevent disposal-related injuries.
- VanishPoint® syringes are available in a variety of needle sizes and gauges.
- VanishPoint® tube holders are used with standard blood collection needles and vacuum tubes for safe blood collection.
- Reduced Syringe Deadspace

Studies show that most needlestick injuries occur within seconds after needles are removed from patients.

VanishPoint® Allergy Syringe Tray
VanishPoint® IV Catheter

Retractable Technologies, Inc.
www.vanishpoint.com
511 Lobo Lane • Little Elm, Texas 75068-0009 • USA
Tel: (972) 221-6644 • Fax: (972) 294-4400
Toll Free: 1-888-703-1010
rtisales@vanishpoint.com • rti.intl@vanishpoint.com

VanishPoint® The New Standard for Safety®
Novice Practitioner Day
NP1(F) The ABC’s of Infection Control
NP2 - Core Competencies For ICPs
NP3 - Core Competencies For Healthcare Workers
NP4 - Critical Thinking - Moving From Black to White to Grey
NP5 - Internet Resources 101
NP6(F) - Overview of the Audit Process
NP7(F) - Audit Tools
NP8(F) - Sharing Results to Implement Changes

Plenary Sessions
P1 - Keynote - Dr. Samantha Nutt
P2 - MRSA - International Lessons Learned
P3 - C. difficile Consensus Conference Recommendations
P4 - Leadership Moving From Attitude To Implementation
P5 - Professional Practice Standards - Newly Revised
P6 - The Challenge of the New IP&C Accreditation Standard
P7 - Efforts in Dealing With Hospital Cross-Infection
P8 - Team Building
P9 - IP&C Vignettes - Questions That Caused a Pause

Concurrent Sessions
Sterilization and Disinfection
C1 - Third Party Reprocessing

Community Issues
C2 - Jurisdiction and Authority...First Nations Reserves
C3 - Meeting The Challenge Of Implementing IP&C

Long Term Care
C4 - Guidelines for Pet Therapy
C5 - How Do You Spell Help? ORIENTATION!

Clinical Microbiology
C6(F) - From Lab to Clinic
C7 - Specimen Procurement and Handling

Advanced Practitioner Day
AP1(F) - Communication Strategies: Getting...Point Across
AP2 - Costing and Preparation of a Business Case
AP3 - Project Evaluation in Infection Prevention and Control
AP4(F) - The ABCs of Infection Control
AP5 - Empowering and Advancing Your Career

Pre Conference Day
PC1 - The Role of the Environment in Transmission
PC2 - ...From Conference Room to Bedside
PC3(F) - Hygiene and Sanitation - Towards New Horizons
PC4 - Quebec Reference Centre for Sterilization
PC5 - Mini-Symposium
PC6 - Benchmarking
PC7 - Real Time Surveillance
PC8 - Surveillance Programs Across Canada
PC9 - Who Are We?
PC10 - What Are The Challenges?
PC11 - Providing Patient Care With Optimal IP&C Practices
PC12 - PHC an Important Part of the Healthcare Mosaic?
PC13 - PreHospital...Important Pt. Healthcare Mosaic/ Q & A

Preparing For The Pandemic
C8 - Risky Business: Risk Assessment In Rountine Practices

Pediatrics
C10 - Evolution Of IP&C in Pediatrics
C11 - Toy Management - It’s Not Child’s Play!
C12(F) - MRSA OutBreak Management in Neonatal ICU

Oral Presentations
O1 - Space and Design
O2 - Risk Factors For Infection
O3 - Education Strategies For ICPs
O4 - Planning and Teamwork
O5 - Education Across The Continuum
O6 - Hand Hygiene
O7 - Surveillance and Screening
O8 - Environment in IP&C

* All Sessions are in English Unless Marked (F) for French

Name
Address
City &Prov/State
Zip or Postal Code
Phone:
Email:

Please Print CARD No. Clearly  Visa • MasterCard • AMEX

Card no.  Expiry

**New - Downloadable MP3s**
Email instructions will be sent to you for downloading the MP3

Audio CDs @ $15.00 ea. x_____ = $_____
5 CDs @ $12.00 ea. = $60.00
10 CDs @ $10.00 ea. = $100.00
20 plus CDs @ $8.00 ea. = $160.00

Downloadable MP3s @ $8.00 ea. x_____ = $_____
5 MP3s @ $7.00 ea. = $_____ 10 MP3s @ $6.00 ea. = $_____
20 or more MP3s @ $5.00 ea. x_____ = $_____

Full Set of CDs (50%off)(Free Postage) = $400.00 = $_____
Full Set of MP3s (50%off)(Free Postage) = $200.00 = $_____

Postage:
$7.00 for 1st CD/DVD
$1.00 for add. CDs/DVDs ($15.00 Max.)

GST Incl. 100% Warranty TOTAL = $_____

Order Online, Mail or Fax to:
KENNEDY RECORDINGS
537 LESSARD DR., EDMONTON, AB, CANADA T6M 1A9
PH./FAX. (TOLL FREE) 1-888-486-1335/1-866-247-1335

E-MAIL: SALES@KENNEDYRECORDINGS.COM
WEB SITE: WWW.KENNEDYRECORDINGS.COM
Today I learned...

it's time to go passive.


Universal Bevel, a cut above the rest.
- Make insertion more comfortable for you and your patients.
- New needle geometry creates a flexible pathway designed for easier catheter insertion, less tearing and faster healing.

Approach with confidence.
- Universal Bevel allows a wider choice of insertion angles.
- Choose the approach that helps achieve the best results for you and your patient.

Passive is preferred.
You need the best when it comes to safety, so get the high activation rate of our passive system and its proven performance in reducing needlestick injuries.

Take action. Go passive.
Contact your B. Braun representative today to schedule a demonstration. Call 1-877-949-9529 or visit us at www.bpassive.bbraunusa.com.
Our family of latex-free surgical gloves protects against latex allergies and offers a chemical accelerator-free alternative.

Ansell is the only major surgical glove manufacturer that offers surgical gloves that protect against both Type I and Type IV allergies.

Introducing our newest latex-free, powder-free surgical glove, Derma Prene® IsoTouch™. Ansell’s polyisoprene formulation provides the same comfort, fit and feel as natural latex rubber and provides protection against Type I latex allergy.

Be ultra safe with Ansell’s latex-free and accelerator-free surgical glove, Derma Prene® Ultra. Ansell’s neoprene formulation contains no chemical accelerators, eliminating the risk of both Type I and Type IV allergies.

And our latex-free surgical gloves have our SureFit Technology—an Ansell exclusive! They’re simply the best latex-free surgical gloves in the market.

For samples and more details, contact Ansell Customer Service at infoclientcanada@ansell.com or 1 800 363-8340
How to submit an article to the Journal

The Canadian Journal of Infection Control publishes member-supplied articles as feature technical article or as “News from the Field”. All material submitted is reviewed by an editorial board consisting of CHICA-Canada members. If you are not sure about your writing skills, get your ideas down and ask a colleague or member of the editorial board for help. Full requirements for technical articles can be found at http://www.chica.org/inside_cjic_journal.html, but here are some tips for getting started:

1) The author of the content must be clearly identified by name, title and organization and both a telephone number and email address must be supplied for contact purposes.
2) The subject of the material must be relevant to the interests of infection control practitioners.
3) The material should be submitted electronically via email as a Word document.
4) Length of submitted material is to be limited to a maximum of 1,500 words.
5) No part of the submitted material is to include what can be construed as sales-oriented promotion of specific individuals, companies, products or services.
6) Any photographic images to be included with the material must be free and clear of any copyright and must be submitted electronically as JPGs or TIFFs that are high resolution (at least 300 dpi) and a minimum of 6” x 9” in size. Image files should be sent separately, not embedded in the Word document.
7) In the event that the material is accepted for publication in CJIC, the author agrees that the first publication rights for the material belong to CJIC magazine and that any subsequent publishing of the material can only be done after the author or publisher is granted reprint approval in writing from CHICA-Canada and CJIC magazine.

ASSOCIATION NEWS

BE AN AUTHOR FOR THE JOURNAL

If you wish to contribute articles on research or general interest please contact the Clinical Editor:

PAT PIASKOWSKI
807-683-1747
piaskowp@tbh.net
Are you thinking about your safety?

Healthcare needlestick injury is a reality. Terumo Medical Corporation is dedicated to helping healthcare workers greatly reduce the risk of needle sticks. Terumo helps reduce the risk by delivering proven, cost effective safety devices with unparalleled customer support.

• SurGuard² Safety Needles and Syringes
• Surshield® Safety Winged Blood Collection Sets
• Surshield® Safety Winged Infusion Sets

Both SurGuard² and Surshield® feature a unique locking mechanism with one-handed activation to help reduce needlestick injury.

To see how Terumo can help keep you safe, just log-on to www.terumotmp.com/ContactUs and arrange for a hands-on demonstration of our safety devices.
The Registered Nurses’ Foundation of Ontario Molson Canada SARS Memorial Fund providing grants to ICPs

The SARS Memorial Fund for Infection Control Practitioners is a tuition/certification/professional development reimbursement program funded by Molson Canada SARS Concert (2003) and supported by the Ontario Ministry of Health and Long Term Care.

RNFOO manages the SARS Memorial Fund, initiated in January 2005. The fund provides grants to Infection Control Practitioners from any discipline to support them in advancing their knowledge to lead infection control practices within their healthcare settings. Grants can be applied to continuing education, certification/re-certification and professional development.

The fund of $175,000 is to be administered over three years, allowing for the allocation of approximately $58,000 per year in support of individual pursuing formal education and certification in the area of infection control.

See www.rnfoo.org for details.
Can other Surgical Scrubs say as much?

Persistence
I am made to last

Chlorhexidine
I contain two active ingredients

Alcohol
I'm not just another alcohol.

Evidence Based
I'm clinically proven

PIDAC states “Perform surgical hand antisepsis using … an alcohol-based hand rub, with a product ensuring sustained activity…” AORN agrees that for surgical hand antisepsis “… the antiseptic agent should be broad spectrum, fast acting, and have a persistent effect.”

According to WHO and CDC guidelines, “Chlorhexidine has substantial residual activity. Addition of low concentrations (0.5% - 1.0%) of chlorhexidine to alcohol-based preparations results in greater residual activity than alcohol alone.”

It is well established that alcohol alone has no persistent effect. Both the WHO and the CDC state: “Alcohols are rapidly germicidal when applied to the skin, but they have no appreciable persistent (i.e., residual) activity.”

3M™ Avagard™ CHG has clinical studies demonstrating its fast, effective, persistent, and cumulative activity.

This product has been issued the Drug Identification Number (DIN: 02246888) for the use as a Waterless Surgical Scrub.
FREE MediClip™ Trial!

Why choose MediClip?
Clippers can help you avoid nicking or cutting the patient’s skin during preoperative hair removal, helping to reduce the patient’s risk for surgical site infections.

Other reasons to try MediClip
• User instructions are right on the handle for ease of use
• Ergonomic handle design provides a comfortable grip
• Hands-off blade disposal protects the user
• Clean-up is easy with the sealed, waterproof handle
• Smooth surface has no screws, crevices or engraving to trap dirt and debris

Sign up now to conduct your own extensive test of MediClip! Get up to 10 clippers and five cases of blades FREE!*  

Sign up online at www.medline.ca/special/MediClip-Trial.asp or call 1-800-396-6996

* This offer is good from 10/15/2008 to 12/15/2008. It applies to new customers only and is good for up to 10 MediClip Clippers and up to five cases of MediClip blades.

INDUSTRY NEWS

PURELL® Sanitizing Hand Wipes

An easy, safe and affordable way for patients, residents or visitors to clean and sanitize their hands.

• Removes light soils and dirt from hands
• Individually wrapped – can be delivered with meal trays, or left at bedside
• Helps prevent the spread of germs

PURELL Sanitizing Hand Wipes are part of a complete line of gentle and effective hand hygiene products from GOJO Industries. For more information, call 800-321-9647 or visit healthcare.gojo.com.

©2008. GOJO Industries, Inc. All rights reserved. PURELL is a trademark of Johnson & Johnson and is used under license.
INDUSTRY NEWS

From patient to patient...
We can make a difference.

VanishPoint® IV Catheter

The VanishPoint® IV catheter, from Retractable Technologies, Inc., utilizes patented automated retraction technology. It is easy to use and allows for one-handed venipuncture. It contains an integrated safety mechanism that, when activated, quickly retracts the introducer needle, which remains safely retracted inside the housing until disposal, substantially reducing the risk of a needlestick injury. Unlike other IV catheters, VanishPoint® catheters do not require additional components such as sliding sheaths, metal clips, or activation buttons. VanishPoint® catheters are available in a variety of sizes, each color-coded according to international standards to indicate the catheter gauge.

Sizes currently available are 24G x 3/4”, 22G x 1”, 20G x 1-1/4”, and 18G x 1-1/4”. Other sizes will be available soon.

ASSOCIATION NEWS

2009 Virox Technologies Partners Scholarship

Through the financial support of the Virox Technologies Partnerships, 10 CHICA-Canada members were awarded scholarships to attend the 2008 CHICA/AIPI Education Conference in Montreal. CHICA-Canada and its members thank Virox Technologies and their partners Deb Canada, JohnsonDiversey, Steris Corporation, Virox Technologies, and Webber Training for their initiative to make the national education conference accessible to those who may not have otherwise been able to attend.

The Virox Technologies Partnership will again provide a scholarship to assist CHICA-Canada members with attending the 2009 Education Conference in St. John’s, Newfoundland Labrador. The 2009 Virox Technologies Partnership Scholarship application is available on www.chica.org.

The deadline date for applications is January 31, 2009.
Think globally
Share regionally
Act locally

With ever increasing speed, infections from all parts of the globe can be on our doorstep. Today, healthcare is about global solutions; the need for uncovering and sharing international best practices through the work of industry and professional associations. The upcoming 2008 CHICA – Canada Education Conference event is an ideal forum for professional out-reach, to create relationships that build stronger partnerships.

ARAMARK Healthcare salutes this learning opportunity in Montreal.

Every day in over 550 hospitals and healthcare facilities across North America, ARAMARK’s Environmental Services teams work in partnership with Infection Prevention & Control to implement effective infection prevention and control measures. It’s about partnership, working together to protect and improve the health of the people we serve. For ARAMARK, Best Care means Best Environments … it’s all connected.

ARAMARK delivers comprehensive non-clinical services in the areas of: patient food services, retail food services, environmental services, facility operations management, laundry & linen management, central transportation, clinical technology services, office services and call centers.

To learn more about ARAMARK Healthcare or to find out how we can help support your facility’s infection control program, visit us at: www.aramark.ca or call 1-877-4ARAMARK.

Best Care, Best Environments®
<table>
<thead>
<tr>
<th>COMPANY</th>
<th>PAGE</th>
<th>PHONE</th>
<th>E-MAIL ADDRESS</th>
<th>WEB SITE</th>
</tr>
</thead>
<tbody>
<tr>
<td>3M Canada Health Care</td>
<td>200</td>
<td>800-364-3577</td>
<td><a href="mailto:klillico@mmm.com">klillico@mmm.com</a></td>
<td><a href="http://www.3M.ca">www.3M.ca</a></td>
</tr>
<tr>
<td>AMG Medical Inc.</td>
<td>IBC</td>
<td>866-518-6099</td>
<td><a href="mailto:medprodefense@amgmedical.com">medprodefense@amgmedical.com</a></td>
<td><a href="http://www.amgmedical.com">www.amgmedical.com</a></td>
</tr>
<tr>
<td>Angus Medical, Inc.</td>
<td>145</td>
<td>866-418-1689</td>
<td><a href="mailto:Bruce@angusmedical.com">Bruce@angusmedical.com</a></td>
<td><a href="http://www.angusmedical.com">www.angusmedical.com</a></td>
</tr>
<tr>
<td>Ansell Canada</td>
<td>196</td>
<td>800-363-8340</td>
<td><a href="mailto:infoclientcanada@ansell.com">infoclientcanada@ansell.com</a></td>
<td><a href="http://www.ansellhealthcare.com/canada">www.ansellhealthcare.com/canada</a></td>
</tr>
<tr>
<td>Armarck Canada</td>
<td>203</td>
<td>877-427-2627</td>
<td><a href="mailto:mark_heller@aramark.ca">mark_heller@aramark.ca</a></td>
<td><a href="http://www.aramark.ca">www.aramark.ca</a></td>
</tr>
<tr>
<td>ArjoHuntleigh</td>
<td>158</td>
<td>800-665-4831</td>
<td><a href="mailto:info@arjo.ca">info@arjo.ca</a></td>
<td><a href="http://www.ArjoHuntleigh.com">www.ArjoHuntleigh.com</a></td>
</tr>
<tr>
<td>Association for Professionals in Infection Control &amp; Epidemiology</td>
<td>188</td>
<td>202-789-1890</td>
<td><a href="mailto:apicinfo@apic.org">apicinfo@apic.org</a></td>
<td><a href="http://www.apic.org">www.apic.org</a></td>
</tr>
<tr>
<td>B. Braun Medical Inc.</td>
<td>195</td>
<td>877-949-9529</td>
<td><a href="mailto:Jonathan.Braido@bbraun.com">Jonathan.Braido@bbraun.com</a></td>
<td><a href="http://www.bpactive.bbraunusa.com">www.bpactive.bbraunusa.com</a></td>
</tr>
<tr>
<td>Baxter Corporation</td>
<td>155</td>
<td>905-281-6505</td>
<td><a href="mailto:Alanna_harrison@baxter.com">Alanna_harrison@baxter.com</a></td>
<td><a href="http://www.baxter.com">www.baxter.com</a></td>
</tr>
<tr>
<td>BD – Canada</td>
<td>151</td>
<td>800-268-5430</td>
<td><a href="mailto:AnneMarie_Carli@bd.com">AnneMarie_Carli@bd.com</a></td>
<td><a href="http://www.bd.com">www.bd.com</a></td>
</tr>
<tr>
<td>Bio-Safe Skin Products Inc.</td>
<td>177</td>
<td>800-667-0520</td>
<td><a href="mailto:john@biosafe.ca">john@biosafe.ca</a></td>
<td><a href="http://www.biosafe.ca">www.biosafe.ca</a></td>
</tr>
<tr>
<td>Capital Health Authority</td>
<td>159</td>
<td>780-735-3435</td>
<td><a href="mailto:Jennifer.Osinchuk@capitalhealth.ca">Jennifer.Osinchuk@capitalhealth.ca</a></td>
<td><a href="http://www.capitalhealth.ca">www.capitalhealth.ca</a></td>
</tr>
<tr>
<td>Chemspec – Hunnisett</td>
<td>189</td>
<td>800-268-6093</td>
<td><a href="mailto:info@chemspec-canada.com">info@chemspec-canada.com</a></td>
<td><a href="http://www.chemspecworld.com">www.chemspecworld.com</a></td>
</tr>
<tr>
<td>Coloplast Canada Corporation</td>
<td>164</td>
<td>877-820-7008</td>
<td><a href="mailto:cadh@coloplast.com">cadh@coloplast.com</a></td>
<td><a href="http://www.coloplast.ca">www.coloplast.ca</a></td>
</tr>
<tr>
<td>Convatec Canada</td>
<td>172</td>
<td>800-465-6302</td>
<td><a href="mailto:Mary.Dimitratos@bms.com">Mary.Dimitratos@bms.com</a></td>
<td><a href="http://www.convatec.ca">www.convatec.ca</a></td>
</tr>
<tr>
<td>Covidiem Ltd.</td>
<td>161</td>
<td>877-664-8926</td>
<td><a href="mailto:customerservice.canada@covidiem.com">customerservice.canada@covidiem.com</a></td>
<td><a href="http://www.covidiem.com">www.covidiem.com</a></td>
</tr>
<tr>
<td>DEB Canada</td>
<td>183</td>
<td>888-332-7827</td>
<td><a href="mailto:debcanada@debcanada.com">debcanada@debcanada.com</a></td>
<td><a href="http://www.debcanada.com">www.debcanada.com</a></td>
</tr>
<tr>
<td>ECOLAB Healthcare</td>
<td>OBC</td>
<td>800-352-5326</td>
<td><a href="mailto:Angie.jeske@ecolab.com">Angie.jeske@ecolab.com</a></td>
<td><a href="http://www.ecolab.com/healthcare">www.ecolab.com/healthcare</a></td>
</tr>
<tr>
<td>Glo Germ Company</td>
<td>152, 154</td>
<td>800-842-6622</td>
<td><a href="mailto:info@glogerm.com">info@glogerm.com</a></td>
<td><a href="http://www.glogerm.com">www.glogerm.com</a></td>
</tr>
<tr>
<td>GOJO Industries Inc.</td>
<td>186</td>
<td>800-321-9647</td>
<td><a href="mailto:customerservice@GOJO.com">customerservice@GOJO.com</a></td>
<td><a href="http://www.healthcare.GOJO.com">www.healthcare.GOJO.com</a></td>
</tr>
<tr>
<td>Hollister Limited</td>
<td>179</td>
<td>800-263-7400</td>
<td><a href="mailto:Shelly.Lendt@Hollister.com">Shelly.Lendt@Hollister.com</a></td>
<td><a href="http://www.hollister.com">www.hollister.com</a></td>
</tr>
<tr>
<td>Intersteam Technologies</td>
<td>171</td>
<td>800-281-4413</td>
<td><a href="mailto:elle@intersteam.com">elle@intersteam.com</a></td>
<td><a href="http://www.intersteam.com">www.intersteam.com</a></td>
</tr>
<tr>
<td>Inviro Medical Devices, Inc.</td>
<td>190</td>
<td>678-405-4025</td>
<td><a href="mailto:khunlap@inviromedical.com">khunlap@inviromedical.com</a></td>
<td><a href="http://www.inviromedical.com">www.inviromedical.com</a></td>
</tr>
<tr>
<td>Medco Equipment, Inc.</td>
<td>199</td>
<td>800-717-3628</td>
<td><a href="mailto:medcoequipment@email.msn.com">medcoequipment@email.msn.com</a></td>
<td><a href="http://www.medcoequipment.com">www.medcoequipment.com</a></td>
</tr>
<tr>
<td>Medline Canada Corporation</td>
<td>149</td>
<td>800-396-6996</td>
<td><a href="mailto:canada@medline.com">canada@medline.com</a></td>
<td><a href="http://www.medline.com">www.medline.com</a></td>
</tr>
<tr>
<td>Metrex Corp.</td>
<td>174</td>
<td>800-841-1428</td>
<td><a href="mailto:Deborah.Alder@metrex.com">Deborah.Alder@metrex.com</a></td>
<td><a href="http://www.metrex.com">www.metrex.com</a></td>
</tr>
<tr>
<td>PDI - Professional Disposables International</td>
<td>163</td>
<td>800-999-6423</td>
<td><a href="mailto:Bnewman@pdipdi.com">Bnewman@pdipdi.com</a></td>
<td><a href="http://www.pdipdi.com">www.pdipdi.com</a></td>
</tr>
<tr>
<td>Retractable Technologies, Inc.</td>
<td>193</td>
<td>888-700-1010</td>
<td><a href="mailto:Rtsales@vanishpoint.com">Rtsales@vanishpoint.com</a></td>
<td><a href="http://www.vanishpoint.com">www.vanishpoint.com</a></td>
</tr>
<tr>
<td>Rubbermaid Canada</td>
<td>167</td>
<td>800-998-7004</td>
<td><a href="mailto:Numair.Khan@rubbermaid.com">Numair.Khan@rubbermaid.com</a></td>
<td><a href="http://www.rubbermaid.com">www.rubbermaid.com</a></td>
</tr>
<tr>
<td>Sage Products Inc.</td>
<td>146</td>
<td>800-323-2220</td>
<td><a href="mailto:mnygren@sageproducts.com">mnygren@sageproducts.com</a></td>
<td><a href="http://www.sageproducts.com/canada/chg">www.sageproducts.com/canada/chg</a></td>
</tr>
<tr>
<td>Steris Canada Inc.</td>
<td>153</td>
<td>800-661-3937</td>
<td><a href="mailto:ian_pequegnat@steris.com">ian_pequegnat@steris.com</a></td>
<td><a href="http://www.steris.com">www.steris.com</a></td>
</tr>
<tr>
<td>The Stevens Company Limited</td>
<td>178</td>
<td>800-268-0184</td>
<td><a href="mailto:stevens@stevens.ca">stevens@stevens.ca</a></td>
<td><a href="http://www.stevens.ca">www.stevens.ca</a></td>
</tr>
<tr>
<td>Terumo Medical Corporation</td>
<td>198</td>
<td>800-283-7866</td>
<td><a href="mailto:Clermont.Goyette@terumomedical.com">Clermont.Goyette@terumomedical.com</a></td>
<td><a href="http://www.terumomedical.com">www.terumomedical.com</a></td>
</tr>
<tr>
<td>Virox Technologies Inc.</td>
<td>IFC</td>
<td>800-387-7578</td>
<td><a href="mailto:info@virox.com">info@virox.com</a></td>
<td><a href="http://www.virox.com">www.virox.com</a></td>
</tr>
</tbody>
</table>
You protect our health, we’ll protect your hands.

MedPro Defense

To learn more about MedPro Defense gloves, contact your AMG representative, or call our customer service at 1-866-518-6099 or visit us at www.amgmedical.com
COMPREHENSIVE SOLUTIONS
AT EVERY POINT OF CONTACT

In a healthcare environment, where cleanliness is critical to providing quality care, a comprehensive solution is required to reduce healthcare associated infections. Ecolab's Infection Prevention programs help ensure cleanliness is never compromised by providing the products, education and service you need to help reduce infections, improve patient satisfaction and protect your brand.

It's protection where you need it. Call 1.800.352.5326 or visit www.ecolab.com/healthcare.

For hand and skin care, Quik-Care™ Antimicrobial Foaming Hand Rub is formulated to provide effective kill at every application.

- Mild emollients promote skin health
- Fragrance free, dye-free formula absorbs quickly into skin
- No-rinse formula promotes use frequency

©2008 Ecolab Inc. All rights reserved.